<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.1" specific-use="sps-1.9" article-type="research-article" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id specific-use="scielo-v3" pub-id-type="publisher-id">q8ynKSysWvPfZw5KHpFLNQs</article-id>
      <article-id specific-use="scielo-v2" pub-id-type="publisher-id">S0066-782X2026000100608</article-id>
      <article-id pub-id-type="doi">10.36660/abc.20250416</article-id>
      <article-id pub-id-type="other">00608</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigo Original</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Abla&#231;&#227;o por Campo Pulsado para Fibrila&#231;&#227;o Atrial: Experi&#234;ncia Multic&#234;ntrica Inicial no Brasil</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-9670-8748</contrib-id>
          <name>
            <surname>May</surname>
            <given-names>Bruna Miers</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados e Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>An&#225;lise estat&#237;stica</role>
          <role>Reda&#231;&#227;o do manuscrito</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Araujo</surname>
            <given-names>Nilson</given-names>
            <suffix>Junior</suffix>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados e Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>An&#225;lise estat&#237;stica</role>
          <role>Obten&#231;&#227;o de financiamento</role>
          <role>Reda&#231;&#227;o do manuscrito</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-6063-2905</contrib-id>
          <name>
            <surname>Boghossian</surname>
            <given-names>Silvia Helena Cardoso</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados e Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Atie</surname>
            <given-names>Jacob</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados e Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maciel</surname>
            <given-names>Washington A.</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados e Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hardy</surname>
            <given-names>Carina Abigail</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados e Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Forno</surname>
            <given-names>Alexander Romeno Janner Dal</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados e Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>Reda&#231;&#227;o do manuscrito</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Saad</surname>
            <given-names>Eduardo B.</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados e Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff8">
            <sup>8</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Munhoz</surname>
            <given-names>Claudio</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados e Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Paola</surname>
            <given-names>Angelo Amato Vincenzo de</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados e Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff9">
            <sup>9</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-7327-2275</contrib-id>
          <name>
            <surname>Scanavacca</surname>
            <given-names>Mauricio</given-names>
          </name>
          <role>Obten&#231;&#227;o de dados e Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zimerman</surname>
            <given-names>Andre</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados e Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>An&#225;lise estat&#237;stica</role>
          <xref ref-type="aff" rid="aff10">
            <sup>10</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vasconcelos</surname>
            <given-names>Jos&#233; Tarc&#237;sio Medeiros de</given-names>
          </name>
          <role>Obten&#231;&#227;o de dados e Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff11">
            <sup>11</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>d&#8217;Avila</surname>
            <given-names>Andr&#233;</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados e Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>An&#225;lise estat&#237;stica</role>
          <role>Reda&#231;&#227;o do manuscrito</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
        <aff id="aff1">
          <label>1</label>
          <institution content-type="orgname">Hospital SOS Cardio</institution>
          <addr-line>
            <named-content content-type="city">Florian&#243;polis</named-content>
            <named-content content-type="state">SC</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Hospital SOS Cardio, Florian&#243;polis, SC &#8211; Brasil</institution>
        </aff>
        <aff id="aff2">
          <label>2</label>
          <institution content-type="orgname">Rede d&#8217;Or S&#227;o Luiz Hospitais</institution>
          <addr-line>
            <named-content content-type="city">Rio de Janeiro</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Rede d&#8217;Or S&#227;o Luiz Hospitais, Rio de Janeiro, RJ &#8211; Brasil</institution>
        </aff>
        <aff id="aff3">
          <label>3</label>
          <institution content-type="orgname">Hospital Universit&#225;rio Pedro Ernesto</institution>
          <addr-line>
            <named-content content-type="city">Rio de Janeiro</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Hospital Universit&#225;rio Pedro Ernesto, Rio de Janeiro, RJ &#8211; Brasil</institution>
        </aff>
        <aff id="aff4">
          <label>4</label>
          <institution content-type="orgname">Hospital Vitoria</institution>
          <addr-line>
            <named-content content-type="city">Rio de Janeiro</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Hospital Vitoria, Rio de Janeiro, RJ &#8211; Brasil</institution>
        </aff>
        <aff id="aff5">
          <label>5</label>
          <institution content-type="orgname">Universidade Federal do Rio de Janeiro</institution>
          <institution content-type="orgdiv1">Hospital Universit&#225;rio Clementino Fraga Filho</institution>
          <addr-line>
            <named-content content-type="city">Rio de Janeiro</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Universidade Federal do Rio de Janeiro &#8211; Hospital Universit&#225;rio Clementino Fraga Filho, Rio de Janeiro, RJ &#8211; Brasil</institution>
        </aff>
        <aff id="aff6">
          <label>6</label>
          <institution content-type="orgname">Cl&#237;nica S&#227;o Vicente</institution>
          <addr-line>
            <named-content content-type="city">Rio de Janeiro</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Cl&#237;nica S&#227;o Vicente &#8211; Rede D&#8217;Or, Rio de Janeiro, RJ &#8211; Brasil</institution>
        </aff>
        <aff id="aff7">
          <label>7</label>
          <institution content-type="orgname">Instituto do Cora&#231;&#227;o do Hospital das Cl&#237;nicas da Faculdade de Medicina da Universidade de S&#227;o Paulo</institution>
          <addr-line>
            <named-content content-type="city">S&#227;o Paulo</named-content>
            <named-content content-type="state">SP</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Instituto do Cora&#231;&#227;o do Hospital das Cl&#237;nicas da Faculdade de Medicina da Universidade de S&#227;o Paulo, S&#227;o Paulo, SP &#8211; Brasil</institution>
        </aff>
        <aff id="aff8">
          <label>8</label>
          <institution content-type="orgname">Hospital Samaritano</institution>
          <addr-line>
            <named-content content-type="city">Botafogo</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Hospital Samaritano, Botafogo, RJ &#8211; Brasil</institution>
        </aff>
        <aff id="aff9">
          <label>9</label>
          <institution content-type="orgname">Hospital S&#227;o Paulo</institution>
          <institution content-type="orgdiv1">Escola Paulista de Medicina</institution>
          <addr-line>
            <named-content content-type="city">S&#227;o Paulo</named-content>
            <named-content content-type="state">SP</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Hospital S&#227;o Paulo, Escola Paulista de Medicina, S&#227;o Paulo, SP &#8211; Brasil</institution>
        </aff>
        <aff id="aff10">
          <label>10</label>
          <institution content-type="orgname">Hospital Moinhos de Vento</institution>
          <addr-line>
            <named-content content-type="city">Porto Alegre</named-content>
            <named-content content-type="state">RS</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Hospital Moinhos de Vento, Porto Alegre, RS &#8211; Brasil</institution>
        </aff>
        <aff id="aff11">
          <label>11</label>
          <institution content-type="orgname">Hospital Benefic&#234;ncia Portuguesa</institution>
          <addr-line>
            <named-content content-type="city">S&#227;o Paulo</named-content>
            <named-content content-type="state">SP</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Hospital Benefic&#234;ncia Portuguesa, S&#227;o Paulo, SP &#8211; Brasil</institution>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1"><label>Correspond&#234;ncia:</label><bold>Andr&#233; d&#8217;Avila</bold> &#8226; Rodovia, SC-401, 121. CEP <postal-code>88030-000</postal-code>, Itacorubi, Florian&#243;polis, SC &#8211; Brasil Email: <email>adavila@bidmc.harvard.edu</email></corresp>
        <fn fn-type="edited-by">
          <label>Editor respons&#225;vel pela revis&#227;o:</label>
          <p>Gl&#225;ucia Maria Moraes de Oliveira</p>
        </fn>
        <fn fn-type="coi-statement">
          <label>Potencial conflito de interesse</label>
          <p>N&#227;o h&#225; conflito com o presente artigo</p>
        </fn>
      </author-notes>
      <pub-date publication-format="electronic" date-type="pub">
        <day>02</day>
        <month>03</month>
        <year>2026</year>
      </pub-date>
      <pub-date publication-format="electronic" date-type="collection">
        <year>2026</year>
      </pub-date>
      <volume>123</volume>
      <issue>1</issue>
      <elocation-id>e20250416</elocation-id>
      <history>
        <date date-type="received">
          <day>11</day>
          <month>06</month>
          <year>2025</year>
        </date>
        <date date-type="rev-recd">
          <day>07</day>
          <month>10</month>
          <year>2025</year>
        </date>
        <date date-type="accepted">
          <day>05</day>
          <month>11</month>
          <year>2025</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xml:lang="en" xlink:href="https://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p>
        </license>
      </permissions>
      <related-article related-article-type="letter" id="r1" xlink:href="10.36660/abc.20260176" ext-link-type="doi"/>
      <abstract>
        <title>Resumo</title>
        <sec>
          <title>Fundamento:</title>
          <p>A abla&#231;&#227;o por campo pulsado (PFA), uma nova t&#233;cnica de abla&#231;&#227;o por cateter n&#227;o t&#233;rmica, aumenta a seguran&#231;a e a efic&#225;cia da abla&#231;&#227;o de fibrila&#231;&#227;o atrial (FA) em compara&#231;&#227;o com m&#233;todos t&#233;rmicos convencionais. Embora amplamente adotada na Europa e nos Estados Unidos, sua aplica&#231;&#227;o no Brasil &#233; recente e ainda n&#227;o documentada.</p>
        </sec>
        <sec>
          <title>Objetivo:</title>
          <p>Este estudo relata a experi&#234;ncia inicial brasileira com a PFA para tratar pacientes com FA, enfatizando sua r&#225;pida ado&#231;&#227;o e curta curva de aprendizado.</p>
        </sec>
        <sec>
          <title>M&#233;todos:</title>
          <p>Uma an&#225;lise retrospectiva de 394 procedimentos consecutivos realizados por 60 operadores em diversos centros brasileiros foi conduzida. Os dados englobaram a demografia dos pacientes, m&#233;tricas dos procedimentos, a associa&#231;&#227;o dos m&#233;todos de imagem utilizados e os resultados da abla&#231;&#227;o. Uma suban&#225;lise comparou operadores de alto volume (n=139 procedimentos) com os demais (n=255). O n&#237;vel de signific&#226;ncia adotado para as an&#225;lises estat&#237;sticas foi p &lt; 0,05.</p>
        </sec>
        <sec>
          <title>Resultados:</title>
          <p>O tipo de FA predominante foi a FA parox&#237;stica (62%), com isolamento das veias pulmonares (IVP) como o principal set de les&#245;es em 54%. Anestesia geral foi quase universal (98%), e n&#227;o houve complica&#231;&#245;es graves relatadas. Centros de alto volume apresentaram tempos de procedimento e abla&#231;&#227;o significativamente menores (82 &#177; 27 vs. 131 &#177; 76 minutos; p&lt;0,001 e 33 &#177; 14 vs. 50 &#177; 33 minutos; p&lt;0,001, respectivamente), al&#233;m de aplicarem menos les&#245;es adicionais ap&#243;s remapeamento (7% vs. 30%; p&lt;0,001), sugerindo uma r&#225;pida curva de aprendizado.</p>
        </sec>
        <sec>
          <title>Conclus&#227;o:</title>
          <p>A PFA demonstra alta efic&#225;cia aguda, seguran&#231;a e facilidade de ado&#231;&#227;o no Brasil, com uma curva de aprendizado notavelmente curta, conforme evidenciado pela efici&#234;ncia dos operadores de alto volume. Estudos de desfechos a longo prazo s&#227;o necess&#225;rios.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="pt">
        <title>Palavras-chave:</title>
        <kwd>Fibrila&#231;&#227;o Atrial</kwd>
        <kwd>Abla&#231;&#227;o por Cateter</kwd>
        <kwd>Brasil</kwd>
      </kwd-group>
      <funding-group>
        <funding-statement><bold>Fontes de financiamento</bold> O presente estudo n&#227;o teve fontes de financiamento externas.</funding-statement>
      </funding-group>
      <counts>
        <fig-count count="6"/>
        <table-count count="4"/>
        <equation-count count="0"/>
        <ref-count count="16"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <fig id="f3">
      <caption>
        <title>O Registro Brasileiro de Abla&#231;&#227;o por campo pulsado resume 394 procedimentos de abla&#231;&#227;o realizados em 60 centros no Brasil de junho de 2024 a abril de 2025. Mapas tridimensionais mostram o isolamento das veias pulmonares (lado esquerdo &#8211; Carto) e o isolamento adicional da parede posterior (lado direito &#8211; Navx) alcan&#231;ados com esta tecnologia. Registros intracavit&#225;rios (parte inferior da figura) demonstram a entrega dos pulsos, com atividade el&#233;trica em tempo real registrada dentro de uma veia pulmonar (sinais laranja) desaparecendo ap&#243;s a abla&#231;&#227;o. ICT: istmo cavotricusp&#237;deo; IM: istmo mitral; PP: parede posterior.</title>
      </caption>
      <graphic xlink:href=""/>
    </fig>
    <sec sec-type="intro">
      <title>Introdu&#231;&#227;o</title>
      <p>A abla&#231;&#227;o por campo pulsado (PFA) representa um avan&#231;o transformador no manejo da fibrila&#231;&#227;o atrial (FA). Essa t&#233;cnica n&#227;o t&#233;rmica, baseada em cateter, utiliza pulsos el&#233;tricos ultrarr&#225;pidos para causar eletropora&#231;&#227;o irrevers&#237;vel em mi&#243;citos, visando seletivamente o tecido card&#237;aco. Ao evitar a energia t&#233;rmica, essa tecnologia elimina complica&#231;&#245;es raras, mas graves, da abla&#231;&#227;o tradicional, como f&#237;stula atrioesof&#225;gica, paralisia do nervo fr&#234;nico permanente e estenose da veia pulmonar, al&#233;m de melhorar a efic&#225;cia do procedimento.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> O registro MANIFEST-PF, o maior estudo multic&#234;ntrico europeu, relatou uma curva de sobrevida livre de FA de 78% ap&#243;s um &#250;nico procedimento, com maior efic&#225;cia na FA parox&#237;stica (82%) do que na FA persistente (71%) e um tempo m&#233;dio de procedimento de 61 minutos.<sup><xref ref-type="bibr" rid="B2">2</xref></sup> Outros ensaios cl&#237;nicos validaram ainda mais a efic&#225;cia e seguran&#231;a da PFA.<sup><xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref></sup></p>
      <p>No Brasil, estima-se que a FA impacte aproximadamente 5 milh&#245;es de indiv&#237;duos, com uma incid&#234;ncia crescente devido ao envelhecimento da popula&#231;&#227;o e ao aumento de fatores de risco associados, como hipertens&#227;o e diabetes.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> No entanto, o acesso &#224; abla&#231;&#227;o por cateter continua restrito, particularmente em regi&#245;es al&#233;m dos grandes centros urbanos, devido ao alto custo, &#224; escassez de institui&#231;&#245;es especializadas em eletrofisiologia e &#224; forma&#231;&#227;o inadequada de operadores em t&#233;cnicas avan&#231;adas de abla&#231;&#227;o. A aprova&#231;&#227;o do primeiro sistema de PFA pela Ag&#234;ncia Nacional de Vigil&#226;ncia Sanit&#225;ria (ANVISA) em abril de 2024 pode representar uma mudan&#231;a para potencialmente enfrentar esses desafios.</p>
      <p>Embora amplamente adotada em todo o mundo, o uso da tecnologia no Brasil &#233; recente e permanece n&#227;o documentado. Devido a varia&#231;&#245;es na infraestrutura de sa&#250;de, disparidades na experi&#234;ncia dos operadores e uma popula&#231;&#227;o de pacientes com um maior n&#250;mero de comorbidades devido a fatores socioecon&#244;micos,<sup><xref ref-type="bibr" rid="B6">6</xref></sup> a utiliza&#231;&#227;o da PFA no Brasil pode divergir dos Estados Unidos, &#193;sia e Europa em rela&#231;&#227;o a fluxo de trabalho e resultados a longo prazo. Este estudo descreve os primeiros 394 procedimentos de PFA realizados no Brasil.</p>
    </sec>
    <sec sec-type="methods">
      <title>M&#233;todos</title>
      <p>Este registro volunt&#225;rio e prospectivo derivou de 394 procedimentos consecutivos realizados entre 18 de junho de 2024 e 29 de abril de 2025 por 60 operadores participantes. Foram analisados dados demogr&#225;ficos dos pacientes, tipo de FA, m&#233;tricas do procedimento, modalidades de imagem associada, n&#250;mero de aplica&#231;&#245;es de campo pulsado, set de les&#245;es e se les&#245;es adicionais foram necess&#225;rias ap&#243;s remapeamento p&#243;s-abla&#231;&#227;o. Todos os dados foram armazenados de forma an&#244;nima, incluindo identifica&#231;&#227;o de pacientes e operadores. O tempo total do procedimento foi definido como a dura&#231;&#227;o desde o acesso vascular at&#233; a remo&#231;&#227;o do cateter e o tempo de abla&#231;&#227;o desde a primeira at&#233; a &#250;ltima aplica&#231;&#227;o do campo pulsado. Al&#233;m disso, o uso de sistemas de mapeamento eletroanat&#244;mico (EAM) e ecocardiografia intracard&#237;aca (ICE), associado ou n&#227;o ao uso da fluoroscopia, tamb&#233;m foi analisado. Uma an&#225;lise secund&#225;ria comparando os 3 operadores de maior volume (Grupo I = 139 pacientes &#8211; 35%) com o restante (Grupo II = 255 pacientes &#8211; 65%) foi realizada para avaliar o impacto da curva de aprendizado com essa nova abordagem.</p>
      <sec>
        <title>Cateter, bainha e gerador de abla&#231;&#227;o para abla&#231;&#227;o por campo pulsado</title>
        <p>O cateter de abla&#231;&#227;o &#233; um cateter "<italic>over-the-wire</italic>" que consiste em 5 <italic>splines</italic> com 4 eletrodos cada (12F), com uma ponta distal vers&#225;til capaz de adotar 3 configura&#231;&#245;es: uma forma de "cesta", uma de "flor" e uma de "oliva". Essas configura&#231;&#245;es facilitam a adapta&#231;&#227;o a uma ampla variedade de anatomias das veias pulmonares, garantindo contato &#243;timo com o tecido e reprodutibilidade do procedimento em diferentes popula&#231;&#245;es. O design do cateter suporta a avalia&#231;&#227;o de eletrogramas bipolares <italic>intra-spline</italic> e permite a integra&#231;&#227;o com v&#225;rios sistemas de mapeamento card&#237;aco para fornecer visualiza&#231;&#227;o em tempo real do posicionamento, forma e rota&#231;&#227;o do cateter.</p>
        <p>Por meio de uma abordagem transeptal, uma bainha bidirecional com 180 graus de articula&#231;&#227;o &#233; utilizada para navegar o cateter de abla&#231;&#227;o at&#233; o alvo (externo = 16,8F e interno = 13F). A bainha requer uma infus&#227;o constante de solu&#231;&#227;o salina heparinizada para prevenir a forma&#231;&#227;o de trombos e embolia gasosa. O cateter &#233; compat&#237;vel com um gerador de abla&#231;&#227;o, que entrega pulsos de onda bipolares e bif&#225;sicos (<xref ref-type="fig" rid="f1">Figura 1</xref>).</p>
        <fig id="f1">
          <label>Figura 1</label>
          <caption>
            <title>O Sistema de Abla&#231;&#227;o por Campo Pulsado (FARAPULSE&#8482; - Boston Scientific, Natick, EUA) possui um cateter irrigado de 12F, over-the-wire (FARAWAVE&#8482; - Painel A) com uma matriz de eletrodos vers&#225;til que pode assumir a forma de oliva (painel B), flor (painel C) ou cesta (painel D) para se adaptar aos &#243;stios das veias pulmonares. O cateter &#233; guiado ao &#225;trio esquerdo atrav&#233;s de uma pun&#231;&#227;o transseptal usando uma bainha direcion&#225;vel de 16,8F (FARADRIVE&#8482;). O sistema entrega pulsos el&#233;tricos na escala de microssegundos (1,5&#8211;2 kV) em uma forma de onda bif&#225;sica controlada, gerada pelo Gerador de Abla&#231;&#227;o FARASTAR&#8482; (painel E). Cada aplica&#231;&#227;o consiste em uma s&#233;rie de pulsos com 5 pulsos individuais, cada um durando 50&#8211;100 microssegundos, entregues dentro de uma janela de 100&#8211;200 milissegundos. Tipicamente, de 4 a 8 aplica&#231;&#245;es por veia pulmonar asseguram o isolamento completo, com o design do cateter criando les&#245;es transmurais precisas e dur&#225;veis. Este processo induz a eletropora&#231;&#227;o, formando seletivamente poros permanentes nas membranas dos cardiomi&#243;citos, o que resulta na morte celular por apoptose e isolamento el&#233;trico das 4 veias (painel G). O cateter de abla&#231;&#227;o pode ser visualizado por fluoroscopia (painel F), no EAM (painel G) e por ICE (painel H).</title>
          </caption>
          <graphic xlink:href=""/>
        </fig>
      </sec>
      <sec>
        <title>Financiamento</title>
        <p>A pesquisa foi conduzida de acordo com a Declara&#231;&#227;o de Helsinki, independentemente de financiamento ou apoio financeiro de quaisquer entidades. Nenhum relacionamento financeiro, pessoal ou profissional existe que possa ser percebido como influ&#234;ncia na pesquisa, an&#225;lise ou interpreta&#231;&#227;o dos achados apresentados neste estudo. Os dois primeiros autores prepararam o manuscrito. Os autores garantem a precis&#227;o e fidelidade dos dados. Todos os pacientes assinaram um Termo de Consentimento no momento da admiss&#227;o hospitalar, que inclui uma cl&#225;usula clara e espec&#237;fica permitindo o compartilhamento de seus dados pessoais para pesquisa cl&#237;nica, desde que os dados sejam compartilhados de forma an&#244;nima de acordo com a Lei Geral de Prote&#231;&#227;o de Dados (LGPD - Lei n&#176; 13.709/2018). O estudo foi aprovado pelo Centro de Ensino e Pesquisa do Instituto de Cardiologia de Santa Catarina (CEP # 113) e registrado na Plataforma Brasil sob o n&#250;mero CAAE: 89229325.1.0000.0113.</p>
      </sec>
      <sec>
        <title>An&#225;lise estat&#237;stica</title>
        <p>A an&#225;lise estat&#237;stica empregou uma abordagem descritiva. A normalidade dos dados foi avaliada utilizando o teste de Shapiro-Wilk. Todas as vari&#225;veis cont&#237;nuas apresentaram distribui&#231;&#227;o normal e foram reportadas como m&#233;dias &#177; desvios padr&#227;o (DP). Vari&#225;veis categ&#243;ricas foram apresentadas como frequ&#234;ncias e porcentagens. An&#225;lises comparativas foram conduzidas utilizando o teste t de Student n&#227;o pareado para vari&#225;veis cont&#237;nuas e o teste do Qui-quadrado para vari&#225;veis categ&#243;ricas. Todos os testes estat&#237;sticos foram bilaterais, com um limite de p &lt; 0,05 para signific&#226;ncia estat&#237;stica. A an&#225;lise dos dados foi realizada utilizando o software SPSS (vers&#227;o 29.0).</p>
        <p>A metodologia estat&#237;stica para analisar a curva de aprendizado dos procedimentos de PFA excluiu entradas com dados ausentes, avaliando tempo total de procedimento e de abla&#231;&#227;o, e aproximou a experi&#234;ncia do operador pelo n&#250;mero de procedimentos, categorizando tamb&#233;m a complexidade do caso como "Baixa" (FA parox&#237;stica) ou "Alta" (FA persistente/repetida). Um modelo de regress&#227;o logar&#237;tmica foi ajustado ao tempo total do procedimento em rela&#231;&#227;o ao n&#250;mero de procedimentos para cada operador, capturando melhorias r&#225;pidas iniciais e ganhos mais lentos &#224; medida que a experi&#234;ncia aumentava. Redu&#231;&#245;es m&#233;dias de tempo e pontos de plat&#244; foram calculados. A variabilidade foi avaliada por meio de desvios padr&#227;o, compara&#231;&#245;es de complexidade de casos e correla&#231;&#227;o. A metodologia assume um padr&#227;o de aprendizado em lei de pot&#234;ncia e procedimentos independentes, com limita&#231;&#245;es incluindo lacunas de dados para operadores de baixo volume e categoriza&#231;&#227;o simplificada de complexidade.</p>
      </sec>
    </sec>
    <sec sec-type="results">
      <title>Resultados</title>
      <p>Todos os resultados est&#227;o detalhados na <xref ref-type="table" rid="t1">Tabela 1</xref>. A idade m&#233;dia foi de 65 &#177; 12 anos e 64% da coorte eram do sexo masculino. A FA parox&#237;stica foi a principal indica&#231;&#227;o 62% seguida pela FA persistente em 34% dos pacientes. O isolamento das veias pulmonares (IVP) foi o set de les&#245;es predominante exigindo 44 &#177; 10 aplica&#231;&#245;es de campo pulsado e um tempo de abla&#231;&#227;o de 37 &#177; 16 minutos. O isolamento da parede posterior (PP) foi realizado em 168 pacientes (43%) durante o procedimento inicial ou em procedimento redo (p&#243;s recorr&#234;ncia) com 58 &#177; 15 aplica&#231;&#245;es e 45 &#177; 28 minutos de abla&#231;&#227;o.</p>
      <table-wrap id="t1">
        <label>Tabela 1</label>
        <caption>
          <title>Caracter&#237;sticas Cl&#237;nicas dos Pacientes e dos Procedimentos de Abla&#231;&#227;o</title>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup width="33%">
            <col width="1%"/>
            <col/>
            <col/>
          </colgroup>
          <thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000">
            <tr style="background-color:#76B4CF;">
              <th align="left" valign="middle" colspan="2">Caracter&#237;stica</th>
              <th align="center" valign="middle">Valor</th>
            </tr>
          </thead>
          <tbody style="border-bottom: thin solid; border-color: #000000">
            <tr>
              <td align="left" valign="middle" colspan="2">
                <bold>N&#250;mero de procedimentos / Centros</bold>
              </td>
              <td align="center" valign="middle">394 / 60</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle" colspan="2">
                <bold>Idade (anos, m&#233;dia &#177; DP)</bold>
              </td>
              <td align="center" valign="middle">65 &#177; 12</td>
            </tr>
            <tr>
              <td align="left" valign="middle" colspan="2">
                <bold>Homens, n (%)</bold>
              </td>
              <td align="center" valign="middle">252 (64)</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle" colspan="2">
                <bold>Anestesia geral, n (%)</bold>
              </td>
              <td align="center" valign="middle">386 (98)</td>
            </tr>
            <tr>
              <td align="left" valign="middle" colspan="3">
                <bold>Tipo de fibrila&#231;&#227;o atrial, n (%)</bold>
              </td>
            </tr>
            <tr>
              <td align="left" valign="middle"/>
              <td align="left" valign="middle">Parox&#237;stica</td>
              <td align="center" valign="middle">244 (62)</td>
            </tr>
            <tr>
              <td align="left" valign="middle"/>
              <td align="left" valign="middle">Persistente</td>
              <td align="center" valign="middle">136 (34)</td>
            </tr>
            <tr>
              <td align="left" valign="middle"/>
              <td align="left" valign="middle">Redo</td>
              <td align="center" valign="middle">14 (4)</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle" colspan="2">
                <bold>Tempo total do procedimento (min &#177; DP)</bold>
              </td>
              <td align="center" valign="middle">113 &#177; 67</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle"/>
              <td align="left" valign="middle">Isolamento de veias pulmonares</td>
              <td align="center" valign="middle">100 &#177; 41</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle"/>
              <td align="left" valign="middle">IVP + isolamento de parede posterior</td>
              <td align="center" valign="middle">117 &#177; 87</td>
            </tr>
            <tr>
              <td align="left" valign="middle" colspan="2">
                <bold>Tempo de abla&#231;&#227;o (min &#177; DP)</bold>
              </td>
              <td align="center" valign="middle">44 &#177; 29</td>
            </tr>
            <tr>
              <td align="left" valign="middle"/>
              <td align="left" valign="middle">Isolamento de veias pulmonares</td>
              <td align="center" valign="middle">37 &#177; 16</td>
            </tr>
            <tr>
              <td align="left" valign="middle"/>
              <td align="left" valign="middle">IVP + isolamento de parede posterior</td>
              <td align="center" valign="middle">45 &#177; 28</td>
            </tr>
            <tr>
              <td align="left" valign="middle"/>
              <td align="left" valign="middle">N&#250;mero de aplica&#231;&#245;es (n &#177; DP)</td>
              <td align="center" valign="middle">51 &#177; 16</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle" colspan="3">
                <bold>M&#233;todos de imagem, n (%)</bold>
                <xref ref-type="table-fn" rid="TFN1">1</xref>
              </td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle"/>
              <td align="left" valign="middle">Apenas fluoroscopia</td>
              <td align="center" valign="middle">84 (22)</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle"/>
              <td align="left" valign="middle">Fluoroscopia + EAM</td>
              <td align="center" valign="middle">184 (50)</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle"/>
              <td align="left" valign="middle">Fluoroscopia + EAM/ICE (%)</td>
              <td align="center" valign="middle">92 (25)</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle"/>
              <td align="left" valign="middle">Fluoroscopia + ICE (%)</td>
              <td align="center" valign="middle">8 (3)</td>
            </tr>
            <tr>
              <td align="left" valign="middle" colspan="2">
                <bold>Set de les&#245;es, n (%)</bold>
              </td>
              <td align="left" valign="middle"/>
            </tr>
            <tr>
              <td align="left" valign="middle"/>
              <td align="left" valign="middle">Isolamento de veias pulmonares</td>
              <td align="center" valign="middle">212 (54)</td>
            </tr>
            <tr>
              <td align="left" valign="middle"/>
              <td align="left" valign="middle">IVP + isolamento de parede posterior</td>
              <td align="center" valign="middle">168 (43)</td>
            </tr>
            <tr>
              <td align="left" valign="middle"/>
              <td align="left" valign="middle">Les&#245;es adicionais p&#243;s remapeamento&#178;</td>
              <td align="center" valign="middle">72 (26)</td>
            </tr>
            <tr>
              <td align="left" valign="middle"/>
              <td align="left" valign="middle">Complica&#231;&#245;es</td>
              <td align="center" valign="middle">N&#227;o relatadas</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN1">
            <label>1</label>
            <p>Entre pacientes com dados v&#225;lidos (n = 372). &#178;Entre pacientes que utilizaram mapeamento (n = 276). Valores s&#227;o n (%) ou m&#233;dia &#177; DP. Min: minutos; IVP: isolamento de veias pulmonares; EAM: mapeamento eletroanat&#244;mico; ICE: ecocardiograma intracard&#237;aco.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Anestesia geral foi utilizada em todos, exceto em 8 casos (seda&#231;&#227;o profunda). O tempo total m&#233;dio do procedimento foi de 113 &#177; 67 minutos e o tempo de abla&#231;&#227;o foi de 44 &#177; 29 minutos. A fluoroscopia foi utilizada na maioria dos procedimentos e 47 procedimentos (22%) foram exclusivamente guiados por fluoroscopia (tempo m&#233;dio: 25 &#177; 10 minutos). Uma combina&#231;&#227;o de EAM e ICE foi utilizada em 92 procedimentos (25%), enquanto EAM sem ICE foi utilizado em 184 casos (50%). A ecocardiografia transesof&#225;gica foi utilizada em cerca de 30% dos procedimentos para guiar a pun&#231;&#227;o transeptal ou auxiliar no posicionamento do cateter ao redor das veias pulmonares, conforme relatado pelo operador, embora seu uso n&#227;o tenha sido documentado consistentemente.</p>
      <p>Procedimentos sem fluoroscopia foram realizados em 47 (12%) pacientes. Os procedimentos sem fluoroscopia apresentaram um n&#250;mero significativamente maior de aplica&#231;&#245;es (74 &#177; 22 vs. 48 &#177; 12, p &lt; 0,001), tempos de abla&#231;&#227;o e de procedimento total mais longos (53 &#177; 14 vs. 40 &#177; 25 minutos, p = 0,002 e 145 &#177; 37 vs. 106 &#177; 67 minutos, p &lt; 0,001, respectivamente) em compara&#231;&#227;o com procedimentos utilizando fluoroscopia.</p>
      <p>O remapeamento foi realizado em todos os pacientes em que o EAM foi utilizado para guiar o procedimento e aplica&#231;&#245;es adicionais de campo pulsado foram consideradas necess&#225;rias em 26% deles, a crit&#233;rio do operador.</p>
      <p>Aplica&#231;&#245;es de campo pulsado tamb&#233;m foram utilizadas para abla&#231;&#227;o do istmo cavotricusp&#237;deo em 16 pacientes (4%) e do istmo mitral em 6 pacientes (1,5%). A abla&#231;&#227;o tamb&#233;m foi realizada em 14 pacientes que j&#225; tinham sido submetidos a abla&#231;&#227;o por radiofrequ&#234;ncia previamente (4%). Nenhuma complica&#231;&#227;o maior foi relatada durante esta s&#233;rie inicial.</p>
      <p>Um resumo dos achados principais do estudo est&#225; na Figura Central.</p>
      <sec>
        <title>An&#225;lise secund&#225;ria</title>
        <p>Uma an&#225;lise secund&#225;ria comparando os 3 operadores de maior volume (Grupo I = 139 pacientes &#8211; 35%) com o restante do Grupo II (255 pacientes &#8211; 65%) foi realizada para avaliar o impacto da curva de aprendizado com essa nova abordagem (<xref ref-type="fig" rid="f2">Figura 2</xref>).</p>
        <fig id="f2">
          <label>Figura 2</label>
          <caption>
            <title>Distribui&#231;&#227;o dos procedimentos por operador. O eixo x representa os operadores, enquanto o eixo y indica o n&#250;mero total de procedimentos realizados. O Grupo I (&#224; esquerda) inclui centros com maior n&#250;mero de procedimentos, indicando operadores de alto volume. O Grupo II (&#224; direita) inclui centros com menos procedimentos, a maioria abaixo de 10, refletindo operadores de baixo volume.</title>
          </caption>
          <graphic xlink:href=""/>
        </fig>
        <p>Houve uma maior preval&#234;ncia de sexo masculino no Grupo I (Operadores de alto volume), mas nenhuma diferen&#231;a na idade ou tipo de FA. O tempo total do procedimento, o tempo de abla&#231;&#227;o e o n&#250;mero de aplica&#231;&#245;es de PFA foram significativamente menores no Grupo I em compara&#231;&#227;o ao Grupo II (<xref ref-type="table" rid="t2">Tabela 2</xref>). Al&#233;m disso, o Grupo I apresentou um tempo de fluoroscopia reduzido e necessitou de um menor n&#250;mero de aplica&#231;&#245;es adicionais ap&#243;s remapeamento.</p>
        <table-wrap id="t2">
          <label>Tabela 2</label>
          <caption>
            <title>Compara&#231;&#227;o entre operadores de alto e baixo volume</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup width="25%">
              <col/>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000">
              <tr style="background-color:#76B4CF;">
                <th align="left" valign="middle">Vari&#225;veis</th>
                <th align="center" valign="middle">Grupo I<break/> (n=139)</th>
                <th align="center" valign="middle">Grupo II<break/> (n=255)</th>
                <th align="center" valign="middle">Valor p</th>
              </tr>
            </thead>
            <tbody style="border-bottom: thin solid; border-color: #000000">
              <tr>
                <td align="left" valign="middle">Idade (n &#177; DP)</td>
                <td align="center" valign="middle">66 &#177; 11</td>
                <td align="center" valign="middle">64 &#177; 14</td>
                <td align="center" valign="middle">0,29</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle">Homens (%)</td>
                <td align="center" valign="middle">64</td>
                <td align="center" valign="middle">50</td>
                <td align="center" valign="middle">&lt;0,001</td>
              </tr>
              <tr>
                <td align="left" valign="middle">FA parox&#237;stica (%)</td>
                <td align="center" valign="middle">62</td>
                <td align="center" valign="middle">61</td>
                <td align="center" valign="middle">0,24</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle">Tempo Total de Procedimento<break/> (min &#177; DP)</td>
                <td align="center" valign="middle">82 &#177; 27</td>
                <td align="center" valign="middle">131 &#177; 76</td>
                <td align="center" valign="middle">&lt;0,001</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Tempo de abla&#231;&#227;o (min &#177; DP)</td>
                <td align="center" valign="middle">33 &#177; 14</td>
                <td align="center" valign="middle">50 &#177; 33</td>
                <td align="center" valign="middle">&lt;0,001</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle">Tempo de fluoroscopia (min &#177; DP)</td>
                <td align="center" valign="middle">23 &#177; 9</td>
                <td align="center" valign="middle">31 &#177; 18</td>
                <td align="center" valign="middle">&lt;0,001</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Les&#245;es adicionais p&#243;s remapeamento (%)</td>
                <td align="center" valign="middle">7</td>
                <td align="center" valign="middle">30</td>
                <td align="center" valign="middle">&lt;0,001</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle">N&#250;mero de aplica&#231;&#245;es (n &#177; DP)</td>
                <td align="center" valign="middle">48 &#177; 10</td>
                <td align="center" valign="middle">53 &#177; 19</td>
                <td align="center" valign="middle">0,005</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN2">
              <p>Grupo I: Grupo com maior volume de procedimentos de acordo com a Figura 2. Valores s&#227;o % ou m&#233;dia &#177; DP. FA: fibrila&#231;&#227;o atrial; Min: minutos.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec>
        <title>Curva de aprendizado</title>
        <p>A an&#225;lise da curva de aprendizado para procedimentos de PFA com base em um conjunto de dados de 125 procedimentos avaliou o tempo total do procedimento e o tempo de abla&#231;&#227;o, considerando a experi&#234;ncia do operador, a complexidade do caso e o volume de procedimentos. Um modelo de regress&#227;o log&#237;stica quantificou a curva de aprendizado, mostrando um decl&#237;nio acentuado no tempo de procedimento nas primeiras 5&#8211;10 interven&#231;&#245;es, com a maioria dos operadores alcan&#231;ando um plat&#244; ap&#243;s 10&#8211;15 interven&#231;&#245;es, onde as redu&#231;&#245;es de tempo ca&#237;ram para menos de 5%. As redu&#231;&#245;es m&#233;dias de tempo variaram de 5 a 10 minutos por caso para operadores de alto volume. O tempo total do procedimento variou de 42 a 240 minutos (mediana de 90 minutos), e o tempo de abla&#231;&#227;o de 11 a 180 minutos (mediana de 34 minutos), com casos de FA persistente exigindo tempos mais longos (m&#233;dia de 105 minutos versus 80 minutos para FA parox&#237;stica).</p>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>Discuss&#227;o</title>
      <p>O primeiro registro multic&#234;ntrico brasileiro, prospectivo e volunt&#225;rio de 394 procedimentos consecutivos de PFA para FA mostra alta efic&#225;cia aguda, em linha com v&#225;rios estudos internacionais. Nenhuma complica&#231;&#227;o maior foi relatada em nossa s&#233;rie, o que pode ser atribu&#237;do ao pequeno tamanho de amostra e &#224; natureza volunt&#225;ria do registro. No entanto, esses resultados s&#227;o semelhantes ao PULSED AF (0,7%) e superam os ensaios MANIFEST-PF/ADVENT (2,1%).<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B7">7</xref></sup> Os tempos totais de procedimento e de abla&#231;&#227;o foram mais longos do que no MANIFEST-PF, mas compar&#225;veis ao ADVENT (106 minutos no total, 29 minutos de abla&#231;&#227;o) e SPHERE AF (101 minutos no total, 46 minutos de abla&#231;&#227;o).<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B8">8</xref></sup></p>
      <p>Operadores de alto volume demonstraram tempos de procedimento e de abla&#231;&#227;o significativamente mais curtos, com menos les&#245;es adicionais, consistente com os achados de registros europeus e americanos.<sup><xref ref-type="bibr" rid="B9">9</xref></sup> Uma curva de aprendizado acentuada sugere uma integra&#231;&#227;o fluida e eficiente dessa nova tecnologia na pr&#225;tica cl&#237;nica no Brasil.</p>
      <sec>
        <title>Anestesia geral</title>
        <p>Apesar da viabilidade de realizar o procedimento sob seda&#231;&#227;o profunda, o uso quase universal de anestesia geral neste registro tamb&#233;m merece considera&#231;&#227;o. A anestesia geral garante a imobilidade do paciente, o que &#233; cr&#237;tico para o posicionamento preciso do cateter, estabilidade e entrega da les&#227;o.<sup><xref ref-type="bibr" rid="B10">10</xref></sup> Facilita o uso de ecocardiograma e sistemas de mapeamento, minimizando artefatos de movimento do paciente e aumenta o conforto do operador durante procedimentos complexos ou prolongados. Al&#233;m disso, a anestesia geral garante conforto ao paciente, eliminando o risco de dor ou consci&#234;ncia durante a abla&#231;&#227;o, que pode ocorrer com seda&#231;&#227;o inadequada. A anestesia geral tamb&#233;m foi associada a melhores resultados a longo prazo na abla&#231;&#227;o por cateter por radiofrequ&#234;ncia da FA.<sup><xref ref-type="bibr" rid="B11">11</xref></sup> No entanto, a anestesia geral tem desvantagens not&#225;veis, incluindo custos mais altos devido &#224; necessidade de equipamentos especializados, aumento do tempo do procedimento para indu&#231;&#227;o e recupera&#231;&#227;o, riscos potenciais, como complica&#231;&#245;es na via a&#233;rea e tempo de recupera&#231;&#227;o prolongado em pacientes com comorbidades. Em contraste, a seda&#231;&#227;o profunda pode reduzir custos e tempo de procedimento, evitando riscos relacionados &#224; anestesia, mas enfrenta o desafio de manter uma profundidade de seda&#231;&#227;o consistente, o que pode levar a movimentos ou desconforto do paciente, comprometendo potencialmente a precis&#227;o do procedimento. A prefer&#234;ncia pela anestesia geral no Brasil pode refletir a disponibilidade de expertise em anestesiologia em centros urbanos e uma abordagem cautelosa na ado&#231;&#227;o de uma tecnologia nova como a PFA, onde a precis&#227;o &#233; primordial. Essa pr&#225;tica difere de alguns contextos internacionais, especialmente na Europa,<sup><xref ref-type="bibr" rid="B2">2</xref></sup> onde a seda&#231;&#227;o profunda &#233; mais comum (82%).</p>
      </sec>
      <sec>
        <title>Abla&#231;&#227;o sem fluoroscopia</title>
        <p>Apenas 47 (12%) dos procedimentos foram realizados sem fluoroscopia em nossa coorte. Uma abla&#231;&#227;o t&#237;pica de FA usando fluoroscopia entrega aproximadamente 15 mSv de radia&#231;&#227;o, compar&#225;vel a 5&#8211;7 anos de radia&#231;&#227;o de fundo natural de cerca de 2&#8211;3 mSv anualmente. A abla&#231;&#227;o sem o uso de fluoroscopia elimina a exposi&#231;&#227;o &#224; radia&#231;&#227;o, ao mesmo tempo em que mant&#233;m taxas de durabilidade das les&#245;es e de complica&#231;&#245;es compar&#225;veis &#224;s dos procedimentos que utilizam fluoroscopia como guia.<sup><xref ref-type="bibr" rid="B12">12</xref></sup> A precis&#227;o do EAM e do ICE melhora a navega&#231;&#227;o do cateter e a precis&#227;o da les&#227;o, superando a velocidade e familiaridade da fluoroscopia, mas requer expertise espec&#237;fica do operador. Embora a fluoroscopia pare&#231;a permitir procedimentos mais r&#225;pidos e menos entregas de energia, seus riscos de radia&#231;&#227;o tornam os procedimentos sem fluoroscopia uma escolha mais segura e avan&#231;ada, priorizando a sa&#250;de a longo prazo em detrimento da brevidade do procedimento. No entanto, nenhum ensaio cl&#237;nico randomizado ainda comparou diretamente a PFA sem fluoroscopia &#224; guiada por fluoroscopia.</p>
      </sec>
      <sec>
        <title>Ecocardiograma intracard&#237;aco na abla&#231;&#227;o</title>
        <p>O uso de ICE introduz considera&#231;&#245;es de custo significativas, com cateteres de ICE de uso &#250;nico custando aproximadamente US$ 1.500&#8211;US$ 3.000 por procedimento, al&#233;m do custo de capital do equipamento de ultrassom. No Brasil, onde os recursos de sa&#250;de s&#227;o frequentemente limitados, especialmente em centros n&#227;o urbanos, esses custos podem restringir a ado&#231;&#227;o de ICE, potencialmente explicando por que apenas 25% dos procedimentos na nossa coorte utilizaram essa tecnologia. Notavelmente, o ICE tamb&#233;m n&#227;o &#233; rotineiramente utilizado em muitos pa&#237;ses europeus, onde fluoroscopia e sistemas de EAM dominam devido a restri&#231;&#245;es de custo e fluxos de trabalho estabelecidos.<sup><xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B13">13</xref></sup> No entanto, o uso de ICE durante um procedimento de abla&#231;&#227;o de FA foi significativamente associado a uma menor incid&#234;ncia de complica&#231;&#245;es e necessidade de nova abla&#231;&#227;o,<sup><xref ref-type="bibr" rid="B14">14</xref></sup> ressaltando a import&#226;ncia de realizar an&#225;lises de custo-efetividade para justificar a aplica&#231;&#227;o dessa tecnologia em casos de PFA. A reutiliza&#231;&#227;o do cateter de ICE, como ocorre atualmente em todo o mundo, reduziria significativamente os custos no Brasil.</p>
      </sec>
      <sec>
        <title>Centros de alto volume</title>
        <p>Um ponto chave em nosso registro &#233; a acentuada curva de aprendizado associada &#224; ado&#231;&#227;o dessa tecnologia, particularmente evidente no desempenho de operadores de alto volume que alcan&#231;aram tempos de procedimento e de abla&#231;&#227;o significativamente mais curtos e uma menor taxa de les&#245;es adicionais ap&#243;s remapeamento. Essas m&#233;tricas sugerem efici&#234;ncia e precis&#227;o aprimoradas do procedimento com o aumento da experi&#234;ncia, corroboradas por estudos externos que relatam redu&#231;&#227;o dos tempos de procedimento em centros de alto volume e uma curva de aprendizado curta ap&#243;s 10 procedimentos.<sup><xref ref-type="bibr" rid="B15">15</xref></sup></p>
      </sec>
      <sec>
        <title>An&#225;lise comparativa da abla&#231;&#227;o por campo pulsado para fibrila&#231;&#227;o atrial em diferentes regi&#245;es</title>
        <p>A abla&#231;&#227;o de FA por campo pulsado apresenta efic&#225;cia consistente na Europa, Estados Unidos, Brasil e &#193;sia, apesar das diferen&#231;as nas abordagens durante os procedimentos. O registro europeu MANIFEST-PF relatou uma taxa de sobrevida anual livre de recorr&#234;ncia de 78% em pacientes com FA, com uso limitado de ICE, EAM ou anestesia geral, indicando que a efic&#225;cia da PFA n&#227;o depende fortemente dessas ferramentas. Em contraste, os centros dos EUA frequentemente empregam ICE e EAM para imagens detalhadas, como visto no ensaio ADVENT, cujo resultado demonstra uma taxa de sobrevida livre de eventos de 73% para o desfecho composto (arritmias atriais, uso de medicamentos antiarr&#237;tmicos, cardiovers&#227;o ou nova abla&#231;&#227;o).</p>
        <p>Os perfis de seguran&#231;a tamb&#233;m s&#227;o robustos em todas as regi&#245;es. O registro EU-PORIA observou uma taxa de complica&#231;&#245;es de 3,6%, sem les&#245;es esof&#225;gicas, estenose da veia pulmonar ou paralisia persistente do nervo fr&#234;nico. O estudo MANIFEST-17K na Europa relatou complica&#231;&#245;es maiores em 1% de 17.642 pacientes, principalmente tamponamento peric&#225;rdico (0,36%) e eventos vasculares (0,30%). O ensaio ADVENT nos EUA atingiu seu objetivo de seguran&#231;a, mas relatou uma morte devido &#224; perfura&#231;&#227;o card&#237;aca, destacando a necessidade de operadores experientes.</p>
        <p>No Brasil, 75% dos procedimentos de PFA utilizaram EAM, em compara&#231;&#227;o com 33% no registro EU-PORIA da Europa. O EAM foi utilizado na abla&#231;&#227;o da PP em 43% dos casos brasileiros, possivelmente influenciando na decis&#227;o pelo seu isolamento em muitos casos, o que resultou em tempos de procedimento e de abla&#231;&#227;o mais longos. Tempos semelhantes aos de um registro asi&#225;tico onde o uso de EAM (82%) e ICE (90%) resultou em uma taxa de sucesso de 88% em um ano.<sup><xref ref-type="bibr" rid="B16">16</xref></sup> Os dados brasileiros revelaram uma taxa de 26% de les&#245;es adicionais durante o remapeamento p&#243;s-abla&#231;&#227;o, sugerindo isolamento incompleto das veias pulmonares ou da PP. Dado que ressalta os riscos potenciais de confiar exclusivamente na fluoroscopia, especialmente em centros com baixo volume de procedimentos, o que pode levar a uma maior recorr&#234;ncia de FA devido a les&#245;es sub&#243;timas.</p>
      </sec>
      <sec>
        <title>Limita&#231;&#245;es</title>
        <p>Este primeiro registro brasileiro de PFA apresenta v&#225;rias limita&#231;&#245;es, incluindo a aus&#234;ncia de dados de acompanhamento a longo prazo sobre recorr&#234;ncia de FA e a variabilidade na experi&#234;ncia do operador e nos protocolos de cada centro. A submiss&#227;o volunt&#225;ria de dados introduz um potencial vi&#233;s de sele&#231;&#227;o, uma vez que os operadores podem ter relatado apenas casos bem-sucedidos. Pesquisas futuras devem priorizar resultados longitudinais, an&#225;lise de custo-efetividade de estrat&#233;gias de imagem e anestesia, e a otimiza&#231;&#227;o do treinamento para reduzir a variabilidade entre os operadores.</p>
      </sec>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclus&#227;o</title>
      <p>O sistema de abla&#231;&#227;o por campo pulsado demonstra alta efic&#225;cia aguda, seguran&#231;a e facilidade de ado&#231;&#227;o no Brasil, com uma curva de aprendizado notavelmente curta, como evidenciado pela efici&#234;ncia superior dos operadores de alto volume. Esses achados posicionam essa tecnologia como uma nova ferramenta na abla&#231;&#227;o da FA, com potencial para melhorar os resultados dos pacientes e a escalabilidade do procedimento. Estudos a longo prazo s&#227;o essenciais para confirmar os resultados a longo prazo e otimizar os protocolos cl&#237;nicos.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="financial-disclosure" id="fn1">
        <label>Fontes de financiamento</label>
        <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
      </fn>
      <fn fn-type="other" id="fn2">
        <label>incula&#231;&#227;o acad&#234;mica</label>
        <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
      </fn>
      <fn fn-type="other" id="fn3">
        <label>Aprova&#231;&#227;o &#233;tica e consentimento informado</label>
        <p>Este estudo foi aprovado pelo Centro de Ensino e Pesquisa do Instituto de Cardiologia de Santa Catarina (cep # 113) sob o n&#250;mero de protocolo CAAE: 89229325.1.0000.0113. Todos os procedimentos envolvidos nesse estudo est&#227;o de acordo com a Declara&#231;&#227;o de Helsinki de 1975, atualizada em 2013.</p>
      </fn>
      <fn fn-type="other" id="fn4">
        <label>Uso de Intelig&#234;ncia Artificial</label>
        <p>Os autores n&#227;o utilizaram ferramentas de intelig&#234;ncia artificial no desenvolvimento deste trabalho.</p>
      </fn>
    </fn-group>
    <sec sec-type="data-availability" specific-use="data-in-article">
      <title>Disponibilidade de Dados</title>
      <p>Os conte&#250;dos subjacentes ao texto da pesquisa est&#227;o contidos no manuscrito.</p>
    </sec>
    <ref-list>
      <title>Refer&#234;ncias</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chun</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Miklav&#269;i&#269;</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Vlachos</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bordignon</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Scherr</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Jais</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>State-of-the-Art Pulsed Field Ablation for Cardiac Arrhythmias: Ongoing Evolution and Future Perspective</article-title>
          <source>Europace</source>
          <year>2024</year>
          <volume>26</volume>
          <issue>6</issue>
          <fpage>euae134</fpage>
          <lpage>euae134</lpage>
          <pub-id pub-id-type="doi">10.1093/europace/euae134</pub-id>
        </element-citation>
        <mixed-citation>1 Chun KJ, Miklav&#269;i&#269; D, Vlachos K, Bordignon S, Scherr D, Jais P, et al. State-of-the-Art Pulsed Field Ablation for Cardiac Arrhythmias: Ongoing Evolution and Future Perspective. Europace. 2024;26(6):euae134. doi: 10.1093/europace/euae134.</mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turagam</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Neuzil</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Reichlin</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Neven</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Metzner</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes from the MANIFEST-PF Registry</article-title>
          <source>Circulation</source>
          <year>2023</year>
          <volume>148</volume>
          <issue>1</issue>
          <fpage>35</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.123.064959</pub-id>
        </element-citation>
        <mixed-citation>2 Turagam MK, Neuzil P, Schmidt B, Reichlin T, Neven K, Metzner A, et al. Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes from the MANIFEST-PF Registry. Circulation. 2023;148(1):35-46. doi: 10.1161/CIRCULATIONAHA.123.064959.</mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reddy</surname>
              <given-names>VY</given-names>
            </name>
            <name>
              <surname>Gerstenfeld</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Natale</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Whang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Cuoco</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation</article-title>
          <source>N Engl J Med</source>
          <year>2023</year>
          <volume>389</volume>
          <issue>18</issue>
          <fpage>1660</fpage>
          <lpage>1671</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa2307291</pub-id>
        </element-citation>
        <mixed-citation>3 Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C, et al. Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2023;389(18):1660-71. doi: 10.1056/NEJMoa2307291.</mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reddy</surname>
              <given-names>VY</given-names>
            </name>
            <name>
              <surname>Gerstenfeld</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Nair</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Natale</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Saliba</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pulsed Field Ablation for Persistent Atrial Fibrillation: 1-Year Results of ADVANTAGE AF</article-title>
          <source>J Am Coll Cardiol</source>
          <year>2025</year>
          <volume>85</volume>
          <issue>17</issue>
          <fpage>1664</fpage>
          <lpage>1678</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jacc.2025.03.515</pub-id>
        </element-citation>
        <mixed-citation>4 Reddy VY, Gerstenfeld EP, Schmidt B, Nair D, Natale A, Saliba W, et al. Pulsed Field Ablation for Persistent Atrial Fibrillation: 1-Year Results of ADVANTAGE AF. J Am Coll Cardiol. 2025;85(17):1664-78. doi: 10.1016/j.jacc.2025.03.515.</mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oliveira</surname>
              <given-names>GMM</given-names>
            </name>
            <name>
              <surname>Brant</surname>
              <given-names>LCC</given-names>
            </name>
            <name>
              <surname>Polanczyk</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Malta</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Biolo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nascimento</surname>
              <given-names>BR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cardiovascular Statistics - Brazil 2023</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2024</year>
          <volume>121</volume>
          <issue>2</issue>
          <elocation-id>e20240079</elocation-id>
          <pub-id pub-id-type="doi">10.36660/abc.20240079</pub-id>
        </element-citation>
        <mixed-citation>5 Oliveira GMM, Brant LCC, Polanczyk CA, Malta DC, Biolo A, Nascimento BR, et al. Cardiovascular Statistics - Brazil 2023. Arq Bras Cardiol. 2024;121(2):e20240079. doi: 10.36660/abc.20240079.</mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keegan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Aguinaga</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Fenelon</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Uribe</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Diez</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Scanavacca</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The first Latin American Catheter Ablation Registry</article-title>
          <source>Europace</source>
          <year>2015</year>
          <volume>17</volume>
          <issue>5</issue>
          <fpage>794</fpage>
          <lpage>800</lpage>
          <pub-id pub-id-type="doi">10.1093/europace/euu322</pub-id>
        </element-citation>
        <mixed-citation>6 Keegan R, Aguinaga L, Fenelon G, Uribe W, Diez GR, Scanavacca M, et al. The first Latin American Catheter Ablation Registry. Europace. 2015;17(5):794-800. doi: 10.1093/europace/euu322.</mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Verma</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Haines</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Boersma</surname>
              <given-names>LV</given-names>
            </name>
            <name>
              <surname>Sood</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Natale</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Marchlinski</surname>
              <given-names>FE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial</article-title>
          <source>Circulation</source>
          <year>2023</year>
          <volume>147</volume>
          <issue>19</issue>
          <fpage>1422</fpage>
          <lpage>1432</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.123.063988</pub-id>
        </element-citation>
        <mixed-citation>7 Verma A, Haines DE, Boersma LV, Sood N, Natale A, Marchlinski FE, et al. Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial. Circulation. 2023;147(19):1422-32. doi: 10.1161/CIRCULATIONAHA.123.063988.</mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anter</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mansour</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nair</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Taigen</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Neuzil</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dual-Energy Lattice-Tip Ablation System for Persistent Atrial Fibrillation: A Randomized Trial</article-title>
          <source>Nat Med</source>
          <year>2024</year>
          <volume>30</volume>
          <issue>8</issue>
          <fpage>2303</fpage>
          <lpage>2310</lpage>
          <pub-id pub-id-type="doi">10.1038/s41591-024-03022-6</pub-id>
        </element-citation>
        <mixed-citation>8 Anter E, Mansour M, Nair DG, Sharma D, Taigen TL, Neuzil P, et al. Dual-Energy Lattice-Tip Ablation System for Persistent Atrial Fibrillation: A Randomized Trial. Nat Med. 2024;30(8):2303-10. doi: 10.1038/s41591-024-03022-6.</mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schmidt</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Bordignon</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Neven</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Reichlin</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Blaauw</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>EUropean Real-World Outcomes with Pulsed Field Ablation in Patients with Symptomatic Atrial Fibrillation: Lessons from the Multi-Centre EU-PORIA Registry</article-title>
          <source>Europace</source>
          <year>2023</year>
          <volume>25</volume>
          <issue>7</issue>
          <fpage>euad185</fpage>
          <lpage>euad185</lpage>
          <pub-id pub-id-type="doi">10.1093/europace/euad185</pub-id>
        </element-citation>
        <mixed-citation>9 Schmidt B, Bordignon S, Neven K, Reichlin T, Blaauw Y, Hansen J, et al. EUropean Real-World Outcomes with Pulsed Field Ablation in Patients with Symptomatic Atrial Fibrillation: Lessons from the Multi-Centre EU-PORIA Registry. Europace. 2023;25(7):euad185. doi: 10.1093/europace/euad185.</mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuno</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nakano</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ando</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Impact of General Anesthesia on Ablation Catheter Stability during Pulmonary Vein Isolation Based on a Novel Measurement Approach</article-title>
          <source>Sci Rep</source>
          <year>2023</year>
          <volume>13</volume>
          <issue>1</issue>
          <fpage>17204</fpage>
          <lpage>17204</lpage>
          <pub-id pub-id-type="doi">10.1038/s41598-023-44450-7</pub-id>
        </element-citation>
        <mixed-citation>10 Kuno S, Nakano Y, Suzuki Y, Ando H, Suzuki W, Takahashi H, et al. Impact of General Anesthesia on Ablation Catheter Stability during Pulmonary Vein Isolation Based on a Novel Measurement Approach. Sci Rep. 2023;13(1):17204. doi: 10.1038/s41598-023-44450-7.</mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Di Biase</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Conti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mohanty</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bai</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sanchez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Walton</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>General Anesthesia Reduces the Prevalence of Pulmonary Vein Reconnection during Repeat Ablation when Compared with Conscious Sedation: Results from a Randomized Study</article-title>
          <source>Heart Rhythm</source>
          <year>2011</year>
          <volume>8</volume>
          <issue>3</issue>
          <fpage>368</fpage>
          <lpage>372</lpage>
          <pub-id pub-id-type="doi">10.1016/j.hrthm.2010.10.043</pub-id>
        </element-citation>
        <mixed-citation>11 Di Biase L, Conti S, Mohanty P, Bai R, Sanchez J, Walton D, et al. General Anesthesia Reduces the Prevalence of Pulmonary Vein Reconnection during Repeat Ablation when Compared with Conscious Sedation: Results from a Randomized Study. Heart Rhythm. 2011;8(3):368-72. doi: 10.1016/j.hrthm.2010.10.043.</mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Abid</surname>
              <given-names>QU</given-names>
            </name>
            <name>
              <surname>Ravi</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Larsen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Krishnan</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Meta-Analysis of Pulmonary Vein Isolation Ablation for Atrial Fibrillation Conventional vs Low- and Zero-Fluoroscopy Approaches</article-title>
          <source>J Cardiovasc Electrophysiol</source>
          <year>2020</year>
          <volume>31</volume>
          <issue>6</issue>
          <fpage>1403</fpage>
          <lpage>1412</lpage>
          <pub-id pub-id-type="doi">10.1111/jce.14450</pub-id>
        </element-citation>
        <mixed-citation>12 Huang HD, Abid QU, Ravi V, Sharma P, Larsen T, Krishnan K, et al. Meta-Analysis of Pulmonary Vein Isolation Ablation for Atrial Fibrillation Conventional vs Low- and Zero-Fluoroscopy Approaches. J Cardiovasc Electrophysiol. 2020;31(6):1403-12. doi: 10.1111/jce.14450.</mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chaumont</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Laredo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Maury</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Massouli&#233;</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Defaye</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Countrywide Introduction of Pulsed Field Ablation for the Treatment of Atrial Fibrillation: Acute Results from the FRANCE-PFA Registry</article-title>
          <source>Heart Rhythm O2</source>
          <year>2025</year>
          <volume>6</volume>
          <issue>7</issue>
          <fpage>911</fpage>
          <lpage>919</lpage>
          <pub-id pub-id-type="doi">10.1016/j.hroo.2025.04.005</pub-id>
        </element-citation>
        <mixed-citation>13 Chaumont C, Laredo M, Thomas O, Maury P, Massouli&#233; G, Defaye P, et al. Countrywide Introduction of Pulsed Field Ablation for the Treatment of Atrial Fibrillation: Acute Results from the FRANCE-PFA Registry. Heart Rhythm O2. 2025;6(7):911-9. doi: 10.1016/j.hroo.2025.04.005.</mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pimentel</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Rahai</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Maccioni</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Khanna</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Differences in Outcomes among Patients with Atrial Fibrillation Undergoing Catheter Ablation with versus without Intracardiac Echocardiography</article-title>
          <source>J Cardiovasc Electrophysiol</source>
          <year>2022</year>
          <volume>33</volume>
          <issue>9</issue>
          <fpage>2015</fpage>
          <lpage>2047</lpage>
          <pub-id pub-id-type="doi">10.1111/jce.15599</pub-id>
        </element-citation>
        <mixed-citation>14 Pimentel RC, Rahai N, Maccioni S, Khanna R. Differences in Outcomes among Patients with Atrial Fibrillation Undergoing Catheter Ablation with versus without Intracardiac Echocardiography. J Cardiovasc Electrophysiol. 2022;33(9):2015-47. doi: 10.1111/jce.15599.</mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bisignani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schiavone</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Solimene</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Russo</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Filannino</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Magnocavallo</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>National Workflow Experience with Pulsed Field Ablation for Atrial Fibrillation: Learning Curve, Efficiency, and Safety</article-title>
          <source>J Interv Card Electrophysiol</source>
          <year>2024</year>
          <volume>67</volume>
          <issue>9</issue>
          <fpage>2127</fpage>
          <lpage>2136</lpage>
          <pub-id pub-id-type="doi">10.1007/s10840-024-01835-6</pub-id>
        </element-citation>
        <mixed-citation>15 Bisignani A, Schiavone M, Solimene F, Russo AD, Filannino P, Magnocavallo M, et al. National Workflow Experience with Pulsed Field Ablation for Atrial Fibrillation: Learning Curve, Efficiency, and Safety. J Interv Card Electrophysiol. 2024;67(9):2127-36. doi: 10.1007/s10840-024-01835-6.</mixed-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tay</surname>
              <given-names>JCK</given-names>
            </name>
            <name>
              <surname>Tarranza</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Chia</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Pung</surname>
              <given-names>XM</given-names>
            </name>
            <name>
              <surname>Loo</surname>
              <given-names>GJM</given-names>
            </name>
            <name>
              <surname>Teo</surname>
              <given-names>HK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pulsed Field Ablation in Atrial Fibrillation: Initial Experience of the Efficacy and Safety in Pulmonary Vein Isolation and Beyond</article-title>
          <source>J Cardiovasc Dev Dis</source>
          <year>2024</year>
          <volume>11</volume>
          <issue>11</issue>
          <fpage>356</fpage>
          <lpage>356</lpage>
          <pub-id pub-id-type="doi">10.3390/jcdd11110356</pub-id>
        </element-citation>
        <mixed-citation>16 Tay JCK, Tarranza JL, Chia SY, Pung XM, Loo GJM, Teo HK, et al. Pulsed Field Ablation in Atrial Fibrillation: Initial Experience of the Efficacy and Safety in Pulmonary Vein Isolation and Beyond. J Cardiovasc Dev Dis. 2024;11(11):356. doi: 10.3390/jcdd11110356.</mixed-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="S1" xml:lang="en">
    <front-stub>
      <article-id pub-id-type="doi">10.36660/abc.20250416i</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Brazilian Registry of Pulsed Field Catheter Ablation for the Treatment of Patients with Atrial Fibrillation</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-9670-8748</contrib-id>
          <name>
            <surname>May</surname>
            <given-names>Bruna Miers</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data and Critical revision of the manuscript for content</role>
          <role>Analysis and interpretation of the data</role>
          <role>Statistical analysis</role>
          <role>Writing of the manuscript</role>
          <xref ref-type="aff" rid="aff12">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Araujo</surname>
            <given-names>Nilson</given-names>
            <suffix>Junior</suffix>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data and Critical revision of the manuscript for content</role>
          <role>Analysis and interpretation of the data</role>
          <role>Statistical analysis</role>
          <role>Obtaining financing</role>
          <role>Writing of the manuscript</role>
          <xref ref-type="aff" rid="aff13">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-6063-2905</contrib-id>
          <name>
            <surname>Boghossian</surname>
            <given-names>Silvia Helena Cardoso</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data and Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff14">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff15">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Atie</surname>
            <given-names>Jacob</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data and Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff16">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maciel</surname>
            <given-names>Washington A.</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data and Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff17">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hardy</surname>
            <given-names>Carina Abigail</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data and Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff18">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Forno</surname>
            <given-names>Alexander Romeno Janner Dal</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data and Critical revision of the manuscript for content</role>
          <role>Analysis and interpretation of the data</role>
          <role>Writing of the manuscript</role>
          <xref ref-type="aff" rid="aff12">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Saad</surname>
            <given-names>Eduardo B.</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data and Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff19">
            <sup>8</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Munhoz</surname>
            <given-names>Claudio</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data and Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff13">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Paola</surname>
            <given-names>Angelo Amato Vincenzo de</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data and Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff20">
            <sup>9</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-7327-2275</contrib-id>
          <name>
            <surname>Scanavacca</surname>
            <given-names>Mauricio</given-names>
          </name>
          <role>Acquisition of data and Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff18">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zimerman</surname>
            <given-names>Andre</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data and Critical revision of the manuscript for content</role>
          <role>Analysis and interpretation of the data</role>
          <role>Statistical analysis</role>
          <xref ref-type="aff" rid="aff21">
            <sup>10</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vasconcelos</surname>
            <given-names>Jos&#233; Tarc&#237;sio Medeiros de</given-names>
          </name>
          <role>Acquisition of data and Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff22">
            <sup>11</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>d&#8217;Avila</surname>
            <given-names>Andr&#233;</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data and Critical revision of the manuscript for content</role>
          <role>Analysis and interpretation of the data</role>
          <role>Statistical analysis</role>
          <role>Writing of the manuscript</role>
          <xref ref-type="aff" rid="aff12">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="c2"/>
        </contrib>
        <aff id="aff12">
          <label>1</label>
          <addr-line>
            <named-content content-type="city">Florian&#243;polis</named-content>
            <named-content content-type="state">SC</named-content>
          </addr-line>
          <country country="BR">Brazil</country>
          <institution content-type="original">Hospital SOS Cardio, Florian&#243;polis, SC &#8211; Brazil</institution>
        </aff>
        <aff id="aff13">
          <label>2</label>
          <addr-line>
            <named-content content-type="city">Rio de Janeiro</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brazil</country>
          <institution content-type="original">Rede d&#8217;Or S&#227;o Luiz Hospitais, Rio de Janeiro, RJ &#8211; Brazil</institution>
        </aff>
        <aff id="aff14">
          <label>3</label>
          <addr-line>
            <named-content content-type="city">Rio de Janeiro</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brazil</country>
          <institution content-type="original">Hospital Universit&#225;rio Pedro Ernesto, Rio de Janeiro, RJ &#8211; Brazil</institution>
        </aff>
        <aff id="aff15">
          <label>4</label>
          <addr-line>
            <named-content content-type="city">Rio de Janeiro</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brazil</country>
          <institution content-type="original">Hospital Vitoria, Rio de Janeiro, RJ &#8211; Brazil</institution>
        </aff>
        <aff id="aff16">
          <label>5</label>
          <addr-line>
            <named-content content-type="city">Rio de Janeiro</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brazil</country>
          <institution content-type="original">Universidade Federal do Rio de Janeiro &#8211; Hospital Universit&#225;rio Clementino Fraga Filho, Rio de Janeiro, RJ &#8211; Brazil</institution>
        </aff>
        <aff id="aff17">
          <label>6</label>
          <addr-line>
            <named-content content-type="city">Rio de Janeiro</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brazil</country>
          <institution content-type="original">Cl&#237;nica S&#227;o Vicente &#8211; Rede D&#8217;Or, Rio de Janeiro, RJ &#8211; Brazil</institution>
        </aff>
        <aff id="aff18">
          <label>7</label>
          <addr-line>
            <named-content content-type="city">S&#227;o Paulo</named-content>
            <named-content content-type="state">SP</named-content>
          </addr-line>
          <country country="BR">Brazil</country>
          <institution content-type="original">Instituto do Cora&#231;&#227;o do Hospital das Cl&#237;nicas da Faculdade de Medicina da Universidade de S&#227;o Paulo, S&#227;o Paulo, SP &#8211; Brazil</institution>
        </aff>
        <aff id="aff19">
          <label>8</label>
          <addr-line>
            <named-content content-type="city">Botafogo</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brazil</country>
          <institution content-type="original">Hospital Samaritano, Botafogo, RJ &#8211; Brazil</institution>
        </aff>
        <aff id="aff20">
          <label>9</label>
          <addr-line>
            <named-content content-type="city">S&#227;o Paulo</named-content>
            <named-content content-type="state">SP</named-content>
          </addr-line>
          <country country="BR">Brazil</country>
          <institution content-type="original">Hospital S&#227;o Paulo, Escola Paulista de Medicina, S&#227;o Paulo, SP &#8211; Brazil</institution>
        </aff>
        <aff id="aff21">
          <label>10</label>
          <addr-line>
            <named-content content-type="city">Porto Alegre</named-content>
            <named-content content-type="state">RS</named-content>
          </addr-line>
          <country country="BR">Brazil</country>
          <institution content-type="original">Hospital Moinhos de Vento, Porto Alegre, RS &#8211; Brazil</institution>
        </aff>
        <aff id="aff22">
          <label>11</label>
          <addr-line>
            <named-content content-type="city">S&#227;o Paulo</named-content>
            <named-content content-type="state">SP</named-content>
          </addr-line>
          <country country="BR">Brazil</country>
          <institution content-type="original">Hospital Benefic&#234;ncia Portuguesa, S&#227;o Paulo, SP &#8211; Brazil</institution>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c2"><label>Mailing Address:</label><bold>Andr&#233; d&#8217;Avila</bold> &#8226; Rodovia, SC-401, 121. Postal Code <postal-code>88030-000</postal-code>, Itacorubi, Florian&#243;polis, SC &#8211; Brasil Email: <email>adavila@bidmc.harvard.edu</email></corresp>
        <fn fn-type="coi-statement">
          <label>Potential conflict of interest</label>
          <p>No potential conflict of interest relevant to this article was reported.</p>
        </fn>
        <fn fn-type="edited-by">
          <label>Editor responsible for the review:</label>
          <p>Gl&#225;ucia Maria Moraes de Oliveira</p>
        </fn>
      </author-notes>
      <related-article related-article-type="letter" id="r1_en" xlink:href="10.36660/abc.20260176i" ext-link-type="doi"/>
      <abstract>
        <title>Abstract</title>
        <sec>
          <title>Background:</title>
          <p>Pulsed field ablation (PFA), a new catheter-based, non-thermal ablation technique, enhances the safety and efficacy of catheter ablation of atrial fibrillation (AF) compared to conventional thermal methods. While widely adopted in Europe and the United States, its application in Brazil is recent and remains undocumented.</p>
        </sec>
        <sec>
          <title>Objective:</title>
          <p>This study reports the initial multicenter Brazilian experience with the pulse field ablation to treat patients with AF, emphasizing its rapid adoption and short learning curve.</p>
        </sec>
        <sec>
          <title>Methods:</title>
          <p>A retrospective analysis of 394 consecutive procedures, performed by 60 operators across multiple Brazilian centers, was conducted. Data encompassed patient demographics, procedural metrics, imaging modalities, and ablation outcomes. A sub-analysis compared high-volume operators (n=139 procedures) with others (n=255). All statistical tests were two-tailed, with a p-value threshold of &lt;0.05 for statistical significance.</p>
        </sec>
        <sec>
          <title>Results:</title>
          <p>Paroxysmal AF was predominant (62%), with pulmonary vein isolation (PVI) only as the primary lesion set in 54%. General anesthesia was near-universal (98%), and no major complications occurred. High-volume centers had significantly shorter procedure and ablation times (82 &#177; 27 vs. 131 &#177; 76 minutes; p&lt;0.001 and 33 &#177; 14 vs. 50 &#177; 33 minutes; p&lt;0.001, respectively), alongside fewer additional lesions after remapping (7% vs. 30%; p&lt;0.001), suggesting a rapid learning curve.</p>
        </sec>
        <sec>
          <title>Conclusion:</title>
          <p>Pulsed field ablation demonstrates high acute efficacy, safety, and ease of adoption in Brazil, with a notably short learning curve, as evidenced by the efficiency of high-volume operators. Long-term outcome studies are warranted.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords:</title>
        <kwd>Atrial Fibrillation</kwd>
        <kwd>Catheter Ablation</kwd>
        <kwd>Brazil</kwd>
      </kwd-group>
      <funding-group>
        <funding-statement><bold>Sources of funding</bold> There were no external funding sources for this study.</funding-statement>
      </funding-group>
    </front-stub>
    <body>
      <sec sec-type="intro">
        <title>Introduction</title>
        <p>Pulsed field ablation (PFA) represents a transformative advance in the management of atrial fibrillation (AF). This new, catheter-based, non-thermal technique uses ultrafast electrical pulses to cause irreversible electroporation in cardiac myocytes, selectively targeting heart tissue. By avoiding thermal energy, PFA eliminates rare but serious complications of traditional AF ablation, such as left-atrial esophageal fistula, permanent phrenic nerve paralysis, and pulmonary vein stenosis, while improving procedural efficacy and efficiency.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> The MANIFEST-PF registry, the largest European multicenter study, reported a survival free of AF curve of 78% after a single procedure, with higher efficacy in paroxysmal AF (82%) than persistent AF (71%) and a median procedure time of 61 minutes.<sup><xref ref-type="bibr" rid="B2">2</xref></sup> Other early trials further validated PFA's efficacy and safety.<sup><xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref></sup></p>
        <p>In Brazil, AF is estimated to impact approximately 5 million individuals, with an increasing prevalence due to an aging population and the rising incidence of associated risk factors, such as hypertension and diabetes.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> However, access to catheter ablation remains constrained, particularly in regions beyond major urban centers, owing to elevated costs, a scarcity of specialized electrophysiology facilities, and inadequate training of operators in advanced ablation techniques. The approval of the first PFA system by the Brazilian Health Regulatory Agency (ANVISA) in April 2024 may represent a potential change in addressing these challenges.</p>
        <fig id="f6">
          <caption>
            <title>The Brazilian PFA Registry summarizes 394 pulsed field ablation (PFA) procedures performed across 60 centers in Brazil from June 2024 to April 2025. Three-dimensional maps depict pulmonary vein isolation (left side - Carto) and additional posterior wall isolation (right side - Navx) achieved with PFA. Intracardiac tracings (bottom) show PFA delivery, with real-time electrical activity recorded from within a pulmonary vein (orange signals) vanishing after ablation, leaving only far-field signals. PVI: pulmonary vein isolation; AF: atral fibrillation; CTI: cavotricuspid isthmus; MI: mitral isthmus; PW: posterior wall.</title>
          </caption>
          <graphic xlink:href=""/>
        </fig>
        <p>While widely adopted worldwide, PFA use in Brazil is recent and remains undocumented. Due to variations in healthcare infrastructure, disparities in operator experience, and a patient population with potentially higher comorbidities driven by socioeconomic factors,<sup><xref ref-type="bibr" rid="B6">6</xref></sup> PFA utilization in Brazil may diverge from that of the United States, Asia, and Europe regarding its workflow and long-term results. This study describes the first 394 PFA procedures performed in Brazil across multiple centers.</p>
      </sec>
      <sec sec-type="methods">
        <title>Methods</title>
        <p>This voluntary, prospective registry was derived from 394 consecutive procedures conducted between June 18, 2024, and April 29, 2025, by 60 participating operators. Patient demographics, AF type, procedural metrics, imaging modalities, number of PFA applications, type of lesion sets, and whether additional lesions were needed upon remap were analyzed. All data were stored anonymously, including patient and operator identification. Total procedure time was defined as the duration from vascular access to catheter removal and ablation time from the first to the last PFA application. Additionally, the use of electroanatomic mapping systems (EAM) and intracardiac echocardiography (ICE), along with fluoroscopy, was also analyzed. A secondary analysis comparing the 3 highest volume operators (Group I = 139 patients &#8211; 35%) with the remaining Group II (255 patients &#8211; 65%) was performed to assess the impact of a learning curve with this new approach.</p>
        <sec>
          <title>Catheter, transeptal sheath, and ablation generator for pulsed field ablation</title>
          <p>The Ablation Catheter is an over-the-wire, pentaspline catheter (12F) with a versatile distal end capable of adopting 3 configurations: a "basket", a "flower", and an "olive" shape. These configurations facilitate adaptation to a wide range of pulmonary vein anatomies, ensuring optimal tissue contact and procedural reproducibility across diverse patient populations. The catheter's design supports the assessment of intra-spline bipolar electrograms, allowing integration with several cardiac mapping systems to provide real-time visualization of catheter placement, shape, and rotation.</p>
          <p>Via a transseptal approach, a bidirectional steerable sheath with 180 degrees of articulation is utilized to navigate the ablation catheter to targeted cardiac anatomy (OD = 16.8F and ID = 13F). The sheath requires a constant heparinized saline infusion to prevent thrombus formation and air embolism. The catheter is compatible with an ablation generator, which delivers proprietary bipolar and biphasic waveforms (<xref ref-type="fig" rid="f4">Figure 1</xref>).</p>
          <fig id="f4">
            <label>Figure 1</label>
            <caption>
              <title>The Pulsed Field Ablation System (FARAPULSE&#8482; - Boston Scientific, Natick, USA) features a 12F, over-the-wire, irrigated catheter (FARAWAVE&#8482; - Panel A) with a versatile electrode array that can form an olive (panel B), flower (panel C), or basket (panel D) shape to conform to the pulmonary vein ostia. The catheter is guided into the left atrium through a transseptal puncture using a 16.8F steerable sheath (FARADRIVE&#8482;). The system delivers microsecond-scale electrical pulses (1.5&#8211;2 kV) in a controlled, biphasic waveform, generated by the FARASTAR&#8482; Ablation Generator (panel E). Each application consists of a pulse train with 5 individual pulses, each lasting 50&#8211;100 microseconds, delivered within a 100&#8211;200 millisecond window. Typically, 4&#8211;8 applications per pulmonary vein ensure complete isolation. This process induces electroporation, selectively forming permanent pores in cardiomyocyte membranes, which will eventually result in cell death by apoptosis (panel G). The ablation catheter can be visualized by fluoroscopy (panel F &#8211; frames provided by A dal Forno), at the EAM (panel G &#8211; provided by BM May), and by ICE (panel H &#8211; frame provided by EB Saad). PA: Postero-anterior; PV: pulmonary veins; L: left; R: right.</title>
            </caption>
            <graphic xlink:href=""/>
          </fig>
        </sec>
        <sec>
          <title>Funding</title>
          <p>The research was conducted in accordance with the Helsinki Declaration, independently of funding or financial support from any entities. No financial, personal, or professional relationships exist that could be perceived to influence the research, analysis, or interpretation of the findings presented in this study. The first two authors prepared the manuscript. The authors vouch for the accuracy, completeness, and fidelity of the data. All patients signed a Consent Form upon hospital admission, which includes a clear and specific clause permitting the sharing of their personal data for clinical research, provided the data is anonymized in accordance with the General Data Protection Law (LGPD - Law No. 13.709/2018). The study was approved by our IRB (Instituto de Cardiologia de Santa Catarina &#8211; CEP # 113) and registered at Plataforma Brazil under CAAE: 89229325.1.0000.0113.</p>
        </sec>
        <sec>
          <title>Statistical analysis</title>
          <p>The statistical analysis employed a primarily descriptive approach. Continuous variables were reported as means &#177; standard deviations (SD), as all variables exhibited normal distribution, confirmed by the Shapiro-Wilk test. Categorical variables were presented as frequencies and percentages. Comparative analyses were conducted using the unpaired Student's t-test for continuous variables and the Chi-squared test for categorical variables. All statistical tests were two-tailed, with a p-value threshold of &lt;0.05 for statistical significance. Data analyses were performed using SPSS software (version 29.0).</p>
          <p>The statistical methodology for analyzing the learning curve of PFA procedures excluded entries with missing dates, total procedure and ablation times, and approximated operator experience with procedure numbers while categorizing case complexity as "Low" (paroxysmal AF) or "High" (persistent/re-do AF). A logarithmic regression model was fitted to total procedure time against procedure number for each operator, capturing rapid initial improvements and slower gains as experience increased, with parameters estimated via least squares. Average time reductions and plateau points were calculated. Variability was assessed through standard deviations, case complexity comparisons, and correlation. The methodology assumes a power-law learning pattern and independent procedures, with limitations including data gaps for low-volume operators and simplified complexity categorization.</p>
        </sec>
      </sec>
      <sec sec-type="results">
        <title>Results</title>
        <p>All the results are detailed in <xref ref-type="table" rid="t3">Table 1</xref>. The mean age was 65 &#177; 12 years, and 64% of the cohort were male. Paroxysmal AF was the primary indication in 62%, followed by persistent AF in 34% of the patients.</p>
        <table-wrap id="t3">
          <label>Table 1</label>
          <caption>
            <title>Clinical and Procedural Characteristics of Pulsed Field Ablation Procedures</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup width="33%">
              <col width="1%"/>
              <col/>
              <col/>
            </colgroup>
            <thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000">
              <tr style="background-color:#76B4CF;">
                <th align="left" valign="middle" colspan="2">Characteristic</th>
                <th align="center" valign="middle">Value</th>
              </tr>
            </thead>
            <tbody style="border-bottom: thin solid; border-color: #000000">
              <tr>
                <td align="left" valign="middle" colspan="2">
                  <bold>Number of Procedures / Operators</bold>
                </td>
                <td align="center" valign="middle">394 / 60</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle" colspan="2">
                  <bold>Age (years, mean &#177; SD)</bold>
                </td>
                <td align="center" valign="middle">65 &#177; 12</td>
              </tr>
              <tr>
                <td align="left" valign="middle" colspan="2">
                  <bold>Male, n (%)</bold>
                </td>
                <td align="center" valign="middle">252 (64)</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle" colspan="2">
                  <bold>General Anesthesia, n (%)</bold>
                </td>
                <td align="center" valign="middle">386 (98)</td>
              </tr>
              <tr>
                <td align="left" valign="middle" colspan="3">
                  <bold>Type of atrial fibrillation, n (%)</bold>
                </td>
              </tr>
              <tr>
                <td align="left" valign="middle"/>
                <td align="left" valign="middle">Paroxysmal</td>
                <td align="center" valign="middle">244 (62)</td>
              </tr>
              <tr>
                <td align="left" valign="middle"/>
                <td align="left" valign="middle">Persistent</td>
                <td align="center" valign="middle">136 (34)</td>
              </tr>
              <tr>
                <td align="left" valign="middle"/>
                <td align="left" valign="middle">Redo</td>
                <td align="center" valign="middle">14 (4)</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle" colspan="2">
                  <bold>Total Procedure Time (min &#177; SD)</bold>
                </td>
                <td align="center" valign="middle">113 &#177; 67</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle"/>
                <td align="left" valign="middle">PVI only</td>
                <td align="center" valign="middle">100 &#177; 41</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle"/>
                <td align="left" valign="middle">PVI + PWI</td>
                <td align="center" valign="middle">117 &#177; 87</td>
              </tr>
              <tr>
                <td align="left" valign="middle" colspan="2">
                  <bold>Ablation Time (min &#177; SD)</bold>
                </td>
                <td align="center" valign="middle">44 &#177; 29</td>
              </tr>
              <tr>
                <td align="left" valign="middle"/>
                <td align="left" valign="middle">PVI only</td>
                <td align="center" valign="middle">37 &#177; 16</td>
              </tr>
              <tr>
                <td align="left" valign="middle"/>
                <td align="left" valign="middle">PVI + PWI</td>
                <td align="center" valign="middle">45 &#177; 28</td>
              </tr>
              <tr>
                <td align="left" valign="middle"/>
                <td align="left" valign="middle">Number of Applications (n &#177; SD)</td>
                <td align="center" valign="middle">51 &#177; 16</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle" colspan="3">
                  <bold>Imaging Techniques, n (%)</bold>
                  <xref ref-type="table-fn" rid="TFN3">1</xref>
                </td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle"/>
                <td align="left" valign="middle">Fluoroscopy Only</td>
                <td align="center" valign="middle">84 (22)</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle"/>
                <td align="left" valign="middle">Fluoroscopy + Mapping</td>
                <td align="center" valign="middle">184 (50)</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle"/>
                <td align="left" valign="middle">Fluoroscopy + Mapping/ICE</td>
                <td align="center" valign="middle">92 (25)</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle"/>
                <td align="left" valign="middle">Fluoroscopy + ICE</td>
                <td align="center" valign="middle">8 (3)</td>
              </tr>
              <tr>
                <td align="left" valign="middle" colspan="2">
                  <bold>Lesion Sets, n (%)</bold>
                </td>
                <td align="left" valign="middle"/>
              </tr>
              <tr>
                <td align="left" valign="middle"/>
                <td align="left" valign="middle">Pulmonary Vein Isolation</td>
                <td align="center" valign="middle">212 (54)</td>
              </tr>
              <tr>
                <td align="left" valign="middle"/>
                <td align="left" valign="middle">Posterior Wall Isolation</td>
                <td align="center" valign="middle">168 (43)</td>
              </tr>
              <tr>
                <td align="left" valign="middle"/>
                <td align="left" valign="middle">Additional Lesions Post-Remapping&#178;</td>
                <td align="center" valign="middle">72 (26)</td>
              </tr>
              <tr>
                <td align="left" valign="middle"/>
                <td align="left" valign="middle">Complications</td>
                <td align="center" valign="middle">Not reported</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN3">
              <label>1</label>
              <p>Among patients with valid data (n = 372). &#178; Among patients who utilized mapping (n = 276). Values are n (%) or mean &#177; SD. PVI: pulmonary vein isolation; PWI: posterior wall isolation; ICE: intracardiac echocardiography.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>Pulmonary vein isolation-only (PVI) was the dominant lesion set requiring 44 &#177; 10 PFA applications and an ablation time of 37 &#177; 16 minutes. Posterior wall isolation was performed in 168 patients (43%) either during the index or a redo procedure, requiring 58 &#177; 15 applications and 45 &#177; 28 minutes of PFA.</p>
        <p>General anesthesia was used in all but 8 cases (deep sedation). Median total procedure time was 113 &#177; 67, and ablation time was 44 &#177; 29 minutes. Fluoroscopy-guided ablation was used in most procedures, and 47 procedures (22%) were exclusively guided by fluoroscopy (mean time: 25 &#177; 10 minutes). A combination of EAM and ICE was utilized in 92 procedures (25%), while EAM without ICE was used in 184 cases (50%). Transesophageal echocardiography (TEE) was used in about 30% of procedures to guide transseptal puncture or assist with catheter positioning around the pulmonary veins, as reported by the operator, though its use was not consistently documented.</p>
        <p>Fluoroless procedures were conducted in 47 (12%) patients. Fluoroless procedures had a significantly higher number of applications (74&#177;22 vs. 48&#177;12, p&lt;0.001), longer ablation and total procedure times (53&#177;14 vs. 40&#177;25 minutes, p=0.002 and 145&#177;37 vs. 106&#177;67 minutes, p&lt;0.001, respectively) as compared to procedures using fluoroscopy.</p>
        <p>Remap was performed in all patients in whom EAM was utilized to guide the procedure, and additional PFA applications were deemed necessary in 26% of them as per the operator's discretion. PFA applications were also utilized to ablate the cavotricuspid isthmus (CTI) in 16 patients (4%) and the mitral isthmus (MI) in 6 patients (1.5%). PFA ablation was performed in 14 patients who had previous RF ablation (4%). No major complications were reported during this initial series.</p>
        <p>A summary of the main findings of the study is presented in the central illustration.</p>
        <sec>
          <title>Secondary analysis</title>
          <p>A secondary analysis comparing the 3 highest volume operators (Group I = 139 patients &#8211; 35%) with the remaining Group II (255 patients &#8211; 65%) was performed to assess the impact of a learning curve with this new approach (<xref ref-type="fig" rid="f5">Figure 2</xref>).</p>
          <fig id="f5">
            <label>Figure 2</label>
            <caption>
              <title>Distribution of procedures by operator. The x-axis represents the operators, while the y-axis indicates the total number of procedures performed. Group I (left) includes operators with higher procedure counts, peaking above 40 procedures, indicating high-volume operators. Group II (right) includes operators with fewer procedures, mostly below 10, reflecting lower-volume centers.</title>
            </caption>
            <graphic xlink:href=""/>
          </fig>
          <p>There was a higher prevalence of male sex in Group I (High-volume operators), but no differences in age. Total procedure time, ablation time, and the number of PFA applications were significantly lower in Group I as compared to Group II (<xref ref-type="table" rid="t4">Table 2</xref>). Moreover, Group I had reduced fluoroscopy time and required a lower number of additional post-remapping PFA applications.</p>
          <table-wrap id="t4">
            <label>Table 2</label>
            <caption>
              <title>Comparison between High and Low Volume Operators</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup width="25%">
                <col/>
                <col/>
                <col/>
                <col/>
              </colgroup>
              <thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000">
                <tr style="background-color:#76B4CF;">
                  <th align="left" valign="middle">Variables</th>
                  <th align="center" valign="middle">Group I<break/> (n=139)</th>
                  <th align="center" valign="middle">Group II<break/> (n=255)</th>
                  <th align="center" valign="middle">p-value</th>
                </tr>
              </thead>
              <tbody style="border-bottom: thin solid; border-color: #000000">
                <tr>
                  <td align="left" valign="middle">Age (n &#177; SD)</td>
                  <td align="center" valign="middle">66 &#177; 11</td>
                  <td align="center" valign="middle">64 &#177; 14</td>
                  <td align="center" valign="middle">0.29</td>
                </tr>
                <tr style="background-color:#C7DFEC;">
                  <td align="left" valign="middle">Male (%)</td>
                  <td align="center" valign="middle">64</td>
                  <td align="center" valign="middle">50</td>
                  <td align="center" valign="middle">&lt;0.001</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Paroxysmal AF (%)</td>
                  <td align="center" valign="middle">62</td>
                  <td align="center" valign="middle">61</td>
                  <td align="center" valign="middle">0.24</td>
                </tr>
                <tr style="background-color:#C7DFEC;">
                  <td align="left" valign="middle">Total Procedure Time (min &#177; SD)</td>
                  <td align="center" valign="middle">82 &#177; 27</td>
                  <td align="center" valign="middle">131 &#177; 76</td>
                  <td align="center" valign="middle">&lt;0.001</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Ablation Time<break/> (min &#177; SD)</td>
                  <td align="center" valign="middle">33 &#177; 14</td>
                  <td align="center" valign="middle">50 &#177; 33</td>
                  <td align="center" valign="middle">&lt;0.001</td>
                </tr>
                <tr style="background-color:#C7DFEC;">
                  <td align="left" valign="middle">Fluoroscopy Time (min &#177; SD)</td>
                  <td align="center" valign="middle">23 &#177; 9</td>
                  <td align="center" valign="middle">31 &#177; 18</td>
                  <td align="center" valign="middle">&lt;0.001</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Additional<break/> Lesions After Remapping (%)</td>
                  <td align="center" valign="middle">7</td>
                  <td align="center" valign="middle">30</td>
                  <td align="center" valign="middle">&lt;0.001</td>
                </tr>
                <tr style="background-color:#C7DFEC;">
                  <td align="left" valign="middle">N&#250;mero de aplica&#231;&#245;es (n &#177; DP)</td>
                  <td align="center" valign="middle">48 &#177; 10</td>
                  <td align="center" valign="middle">53 &#177; 19</td>
                  <td align="center" valign="middle">0.005</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="TFN4">
                <p>Group I: The three highest volume operators according to Figure 2. Values are % or mean &#177; SD. AF: atrial fibrillation; Min: minutes.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec>
          <title>Learning curve</title>
          <p>The learning curve analysis for PFA procedures, based on a dataset of 125 procedures, evaluated total procedure time and ablation time, considering operator experience, case complexity, and procedure volume. A logistic regression model quantified the learning curve, showing a steep initial decline in procedure time over the first 5&#8211;10 procedures, with most operators achieving a plateau after 10&#8211;15 procedures, where time reductions fell below 5%. Average time reductions ranged from 5 to 10 minutes per case for high-volume operators. Total procedure time ranged from 42 to 240 minutes (median 90 minutes), and ablation time from 11 to 180 minutes (median 34 minutes), with persistent AF cases requiring longer times (mean 105 minutes vs. 80 minutes for paroxysmal AF).</p>
        </sec>
      </sec>
      <sec sec-type="discussion">
        <title>Discussion</title>
        <p>The first Brazilian multicenter, prospective, voluntary registry of 394 PFA consecutive procedures for AF shows high acute efficacy in line with several international studies. No major complications were reported in our series, potentially related to our small sample size and reporting bias due to the voluntary nature of the registry. However, these results are similar to PULSED AF (0.7%) and surpass MANIFEST-PF/ADVENT trials (2.1%).<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B7">7</xref></sup> Total procedural and ablation times were longer than in MANIFEST-PF but comparable to ADVENT (106 minutes total, 29 minutes ablation) and SPHERE AF (101 minutes total, 46 minutes ablation).<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B8">8</xref></sup></p>
        <p>High-volume operators demonstrated significantly shorter procedure and ablation times, with fewer additional lesions, consistent with EU-PORIA and U.S. findings.<sup><xref ref-type="bibr" rid="B9">9</xref></sup> A steep learning curve suggests a seamless integration of this novel technology into clinical practice in Brazil.</p>
        <sec>
          <title>General anesthesia</title>
          <p>Despite the feasibility of performing the procedure under deep sedation, the near-universal use of general anesthesia in this registry also warrants consideration. GA ensures patient immobility, which is critical for accurate catheter positioning, stability, and lesion delivery.<sup><xref ref-type="bibr" rid="B10">10</xref></sup> It facilitates the use of ICE and mapping systems by minimizing patient movement artifacts and enhancing operator comfort during complex or prolonged procedures. Furthermore, general anesthesia ensures patient comfort, eliminating the risk of pain or awareness during ablation, which can occur with inadequate sedation. GA has also been associated with better long-term outcomes of radiofrequency catheter ablation of AF.<sup><xref ref-type="bibr" rid="B11">11</xref></sup> However, GA has notable drawbacks, including higher costs due to the need for an anesthesiologist and specialized equipment, increased procedural time for induction and recovery, and potential risks such as airway complications and prolonged recovery time in patients with comorbidities. In contrast, deep sedation may reduce costs and procedural time while avoiding anesthesia-related risks, but it carries the challenge of maintaining consistent sedation depth, which could lead to patient movement or discomfort, potentially compromising procedural accuracy. The preference for general anesthesia in Brazil may reflect the availability of anesthesiology expertise in urban centers and a cautious approach to adopting a novel technology like PFA, where precision is paramount. This practice differs from some international settings,<sup><xref ref-type="bibr" rid="B2">2</xref></sup> especially in Europe, where deep sedation is more common (82%).</p>
        </sec>
        <sec>
          <title>Fluoro-less PFA</title>
          <p>Only 47 (12%) procedures were performed without fluoroscopy guidance in our cohort. A typical AF ablation using fluoroscopy delivers approximately 15 mSv of radiation, comparable to 5&#8211;7 years of natural background radiation of about 2&#8211;3 mSv annually. Fluoro-free AF ablation eliminates radiation exposure while achieving similar durable PVI and complication rates as fluoroscopy-guided methods.<sup><xref ref-type="bibr" rid="B12">12</xref></sup> EAM and ICE's precision enhances catheter navigation and lesion accuracy, outweighing fluoroscopy's speed and familiarity but requires specific operator expertise. While fluoroscopy seems to enable faster procedures and fewer energy deliveries, its radiation risks make fluoro-less procedures a safer and more advanced choice, prioritizing long-term health over procedural brevity. Nevertheless, no randomized clinical trials have yet directly compared fluoro-less to fluoroscopy-guided PFA ablation.</p>
        </sec>
        <sec>
          <title>ICE during PFA</title>
          <p>The use of ICE introduces significant cost considerations, with single-use ICE catheters costing approximately $1,500&#8211;$3,000 per procedure, in addition to the capital expense of ultrasound equipment. In Brazil, where healthcare resources are often constrained, particularly in non-urban centers, these costs may limit ICE adoption, potentially explaining why only 25% of procedures relied on this technology. Notably, ICE is also not routinely used in many European countries, where fluoroscopy and electroanatomic mapping systems dominate due to cost constraints and established workflows.<sup><xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B13">13</xref></sup> However, the use of ICE during an AF ablation procedure was significantly associated with a lower incidence of complications and repeat ablation,<sup><xref ref-type="bibr" rid="B14">14</xref></sup> highlighting the need for cost-effectiveness analyses to justify its use in PFA cases. The reuse of the ICE catheter, as currently done worldwide, would significantly reduce the costs in Brazil.</p>
        </sec>
        <sec>
          <title>High-volume operators</title>
          <p>A key highlight in our registry is the steep learning curve associated with PFA adoption, particularly evident in the performance of high-volume operators who achieved significantly shorter procedure and ablation times and a lower rate of additional lesions post-remapping. These metrics suggest enhanced procedural efficiency and precision with increased experience, corroborated by external studies reporting reduced procedure times in high-volume centers and a short learning curve after 10 procedures.<sup><xref ref-type="bibr" rid="B15">15</xref></sup></p>
        </sec>
        <sec>
          <title>Comparative analysis of pulsed field ablation for atrial fibrillation across regions</title>
          <p>PFA for AF ablation shows consistent efficacy across Europe, the United States, Brazil, and Asia, despite differences in procedural approaches. The MANIFEST-PF registry reported a 78% one-year freedom from atrial arrhythmia recurrence in diverse AF patients, with limited use of ICE, EAM, or general anesthesia, indicating PFA's effectiveness is not heavily reliant on these tools. In contrast, U.S. centers frequently employ ICE and EAM for detailed imaging, as seen in the ADVENT trial, which reported a 73.3% one-year freedom from a composite endpoint (recurrent arrhythmias, antiarrhythmic drug use, cardioversion, or repeat ablation).</p>
          <p>Safety profiles are equally robust across regions. The EU-PORIA registry noted a 3.6% complication rate, with no esophageal issues, pulmonary vein stenosis, or persistent phrenic nerve palsy. The MANIFEST-17K study in Europe reported major complications in 1% of 17,642 patients, mainly pericardial tamponade (0.36%) and vascular events (0.30%). The U.S. ADVENT trial met its safety endpoint but reported one death due to cardiac perforation, emphasizing the need for skilled operators.</p>
          <p>In Brazil, 75% of PFA procedures used EAM, compared to 33% in Europe's EU-PORIA registry. EAM supported posterior wall ablation in 43% of Brazilian cases, leading to longer procedure and ablation times, similar to an Asian registry where EAM (82%) and ICE (90%) use resulted in an 88% one-year success rate.<sup><xref ref-type="bibr" rid="B16">16</xref></sup> Brazilian data revealed a 26% rate of additional lesions during remapping post-ablation, suggesting incomplete pulmonary vein or posterior wall isolation. This highlights potential risks of relying solely on fluoroscopy, especially in low-volume centers, which may increase AF recurrence due to suboptimal lesion sets.</p>
        </sec>
        <sec>
          <title>Limitations</title>
          <p>This first Brazilian PFA registry has several limitations, including the absence of long-term follow-up data on AF recurrence and variability in operator experience and center protocols. The voluntary submission of data introduces potential selection bias, as operators may have reported only successful cases. Future research should prioritize longitudinal outcomes, cost-effectiveness of imaging and anesthesia strategies, and the optimization of training to reduce variability among operators.</p>
        </sec>
      </sec>
      <sec sec-type="conclusions">
        <title>Conclusion</title>
        <p>The pulse field ablation demonstrates high acute efficacy, safety, and ease of adoption in Brazil, with a remarkably short learning curve, as evidenced by the superior efficiency of high-volume operators. These findings position PFA as a new tool in AF ablation, with the potential to enhance patient outcomes and procedural scalability. Long-term studies are essential to confirm its long-term results and optimize clinical protocols.</p>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn fn-type="financial-disclosure" id="fn5">
          <label>Sources of Funding</label>
          <p>There were no external funding sources for this study.</p>
        </fn>
        <fn fn-type="other" id="fn6">
          <label>Study association</label>
          <p>This study is not associated with any thesis or dissertation work.</p>
        </fn>
        <fn fn-type="other" id="fn7">
          <label>Ethics approval and consent to participate</label>
          <p>This study was approved by the Centro de Ensino e Pesquisa do Instituto de Cardiologia de Santa Catarina (CEP # 113) under the protocol number CAAE: 89229325.1.0000.0113. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013.</p>
        </fn>
        <fn fn-type="other" id="fn8">
          <label>Use of Artificial Intelligence</label>
          <p>The authors did not use any artificial intelligence tools in the development of this work.</p>
        </fn>
      </fn-group>
      <sec sec-type="data-availability" specific-use="data-in-article">
        <title>Data Availability Statement</title>
        <p>The underlying content of the research text is contained within the manuscript.</p>
      </sec>
    </back>
  </sub-article>
</article>
